前の章|次の章

がん免疫療法のための生物活性天然化合物によるPD-1/PD-L1シグナル軸の発がんへの役割と標的化

  • role： First author第一作者
  • Affiliation：

    Department of Pharmacognosy and Phytochemistry, School of Pharmaceutical Sciences, Delhi Pharmaceutical Sciences and Research University, New Delhi 110017, India

Yogesh Godiyal1,  
  • Affiliation：

    Department of Pharmacognosy and Phytochemistry, School of Pharmaceutical Sciences, Delhi Pharmaceutical Sciences and Research University, New Delhi 110017, India

Drishti Maheshwari1,  
  • Affiliation：

    Department of Experimental Embryology, Institute of Genetics and Animal Biotechnology of the Polish Academy of Sciences, Jastrzebiec,05-552 Magdalenka, Poland

    African Genome Center, Mohammed VI Polytechnic University, Hay Moulay Rachid, 43150 Ben Guerir, Morocco

Hiroaki Taniguchi23,  
  • Affiliation：

    Department of Pharmacology, College of Osteopathic Medicine, Lake Erie College of Osteopathic Medicine, Bradenton, FL 34211, USA

Shweta S. Zinzuwadia4,  
  • Affiliation：

    Clinical Investigation and Biomedical Research Directions, Center for Genetic Engineering and Biotechnology, 11600 Havana, Cuba

Yanelys Morera-Díaz5,  
  • role： Corresponding author通信作者
  • Affiliation：

    Department of Pharmacognosy and Phytochemistry, School of Pharmaceutical Sciences, Delhi Pharmaceutical Sciences and Research University, New Delhi 110017, India

  • Email：devesh.tewari@dpsru.edu.in
  • Introduction：* Devesh Tewari devesh.tewari@dpsru.edu.in; dtewari3@gmail.com
Devesh Tewari1*,  
  • role： Corresponding author通信作者
  • Affiliation：

    Department of Pharmacology, College of Osteopathic Medicine, Lake Erie College of Osteopathic Medicine, Bradenton, FL 34211, USA

  • Email：abishayee@lecom.edu
  • Introduction：Anupam Bishayee abishayee@lecom.edu; abishayee@gmail.com
Anupam Bishayee4*

サマリー

がんは世界的な健康問題であり、主要な死亡原因の一つです。免疫チェックポイント阻害剤は腫瘍学の分野に革命をもたらし、強力な治療戦略として登場しました。大きな注目を集めている主要な経路は、プログラム細胞死-1（PD-1）/プログラム細胞死リガンド-1（PD-L1）シグナル軸です。腫瘍細胞に発現しているPD-L1とPD-1との相互作用は、自然免疫応答を減少させ、結果として体の免疫システムの能力を損ないます。さらに、これは自然免疫および獲得免疫成分の表現型と機能性を制御します。アベリュマブ、アテゾリズマブ、カムレリズマブ、ドスタルリマブ、デュルバルマブ、シニチリマブ、トリパリマブ、ジンベレリマブを含む一連のモノクローナル抗体が、PD-1とPD-L1の相互作用を標的にして開発されました。これらの薬剤は、どの臓器系にも影響を及ぼす可能性のある自己免疫様の広範な合併症を引き起こすことがあります。最近の研究は、免疫チェックポイントを阻害するさまざまな天然化合物の効果に焦点を当てています。これにより、既存の抗がん薬の武器群に貢献する可能性があります。いくつかの生物活性天然物質はPD-1/PD-L1シグナル軸に影響を与え、腫瘍細胞のアポトーシスを促進し、細胞増殖に影響をおよぼし、最終的には腫瘍細胞の死を引き起こし、がんの進行を抑制することが示されています。しかし、がんの文脈においてPD-1を標的とするさまざまな天然化合物の役割に関しては、かなりの知識ギャップが存在します。したがって、このレビューは、PD-1/PD-L1ブロックと異なる天然分子の抗がん効果との間の共通のつながりを提供することを目的としています。さらに、主な焦点は作用機序および生物活性分子の臨床効果に置かれます。現在の課題とともに、天然物質を介したPD-1/PD-L1相互作用に対する将来の研究方向の範囲についても議論されます。

キーワード

がん;PD-1/PD-L1;クロストーク;天然化合物;治療標的

References

  1. 1..
    Vaghari-Tabari M,Ferns GA,Qujeq D,Andevari AN,Sabahi Z,Moein S. Signaling, metabolism, and cancer: an important relationship for therapeutic intervention. J Cell Physiol. 2021;236(8):5512-32.
  2. 2..
    Siegel RL,Giaquinto AN,Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12-49.
  3. 3..
    Mao JJ,Pillai GG,Andrade CJ,Ligibel JA,Basu P,Cohen L, et al. Integrative oncology: addressing the global challenges of cancer prevention and treatment. CA Cancer J Clin. 2022;72(2):144-64.
  4. 4..
    Wilkinson L,Gathani T. Understanding breast cancer as a global health concern. Br J Radiol. 2022;95(1130):20211033.
  5. 5..
    Cheek DM,Naxerova K. Mapping the long road to cancer. Cell.2022;185(6):939-40.
  6. 6..
    Pilleron S,Soto-Perez-de-Celis E,Vignat J,Ferlay J,Soerjomataram I,Bray F, et al. Estimated global cancer incidence in the oldest adults in 2018 and projections to 2050. Int J cancer. 2021;148(3):601-8.
  7. 7..
    Chen J,Jiang CC,Jin L,Zhang XD. Regulation of PD-L1: a novel role of pro-survival signalling in cancer. Ann Oncol. 2016;27(3):409-16.
  8. 8..
    Ingham PW,McMahon AP. Hedgehog signaling in animal development:paradigms and principles. Genes Dev. 2001;15(23):3059-87.
  9. 9..
    Petrova R,Joyner AL. Roles for Hedgehog signaling in adult organ homeostasis and repair. Development. 2014;141(18):3445-57.
  10. 10..
    Zeng X,Ju D. Hedgehog signaling pathway and autophagy in cancer. Int J Mol Sci. 2018;19(8):2279.
  11. 11..
    Calses PC,Crawford JJ,Lill JR,Dey A. Hippo pathway in cancer:aberrant regulation and therapeutic opportunities. Trends Cancer.2019;5(5):297-307.
  12. 12..
    Tewari D,Nabavi SF,Nabavi SM,Sureda A,Farooqi AA,Atanasov AG, et al. Targeting activator protein 1 signaling pathway by bioactive natural agents: possible therapeutic strategy for cancer prevention and intervention. Pharmacol Res. 2018;128:366-75.
  13. 13..
    Takebe N,Miele L,Harris PJ,Jeong W,Bando H,Kahn M, et al. Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update. Nat Rev Clin Oncol. 2015;12(8):445-64.
  14. 14..
    Majumder S,Crabtree JS,Golde TE,Minter LM,Osborne BA,Miele L. Targeting Notch in oncology: the path forward. Nat Rev Drug Discov.2021;20(2):125-44.
  15. 15..
    Tewari D,Priya A,Bishayee A,Bishayee A. Targeting transforming growth factor-β signalling for cancer prevention and intervention: recent advances in developing small molecules of natural origin. Clin Transl Med. 2022;12(4):e795.
  16. 16..
    Tewari D,Bawari S,Sharma S,DeLiberto LK,Bishayee A. Targeting the crosstalk between canonical Wnt/β-catenin and inflammatory signaling cascades: a novel strategy for cancer prevention and therapy. Pharma-col Ther. 2021;227:107876.
  17. 17..
    Ishida Y,Agata Y,Shibahara K,Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon pro-grammed cell death. EMBO J. 1992;11(11):3887-95.
  18. 18..
    Blank C,Mackensen A. Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion. Cancer Immunol Immunother. 2007;56(5):739-45.
  19. 19..
    Jain P,Jain C,Velcheti V. Role of immune-checkpoint inhibitors in lung cancer. Ther Adv Respir Dis. 2018;12:1753465817750075.
  20. 20..
    Harada K,Yamamoto S,Kato K. Pembrolizumab for the treatment of advanced esophageal cancer. Future Oncol. 2022;18(18):2311-9.
  21. 21..
    Al Hadidi SA,Lee HJ. Pembrolizumab for the treatment of Hodgkin lymphoma. Expert Opin Biol Ther. 2020;20(11):1275-82.
  22. 22..
    Sidaway P. Nivolumab as adjuvant therapy. Nat Rev Clin Oncol.2021;18(8):470.
  23. 23..
    Ak N,Aydiner A. Nivolumab treatment for metastatic thymic epithelial tumors. J Oncol Pharm Pract. 2021;27(7):1710-5.
  24. 24..
    Hamilton G. Avelumab: search for combinations of immune checkpoint inhibition with chemotherapy. Expert Opin Biol Ther. 2021;21(3):311-22.
  25. 25..
    Herbst RS,Giaccone G,de Marinis F,Reinmuth N,Vergnenegre A,Bar-rios CH, et al. Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC. N Engl J Med. 2020;383(14):1328-39.
  26. 26..
    Farzeen Z,Khan RRM,Chaudhry AR,Pervaiz M,Saeed Z,Rasheed S, et al. Dostarlimab: a promising new PD-1 inhibitor for cancer immunother-apy. J Oncol Pharm Pract. 2024;30(8):1411-31.
  27. 27..
    Ma GL,Lin WF. Immune checkpoint inhibition mediated with liposomal nanomedicine for cancer therapy. Mil Med Res. 2023;10(1):20.
  28. 28..
    Singh V,Sheikh A,Abourehab MAS,Kesharwani P. Dostarlimab as a miracle drug: rising hope against cancer treatment. Biosensors.2022;12(8):617.
  29. 29..
    Vesely MD,Zhang T,Chen L. Resistance mechanisms to anti-PD cancer immunotherapy. Annu Rev Immunol. 2022;40:45-74.
  30. 30..
    Nowicki TS,Hu-Lieskovan S,Ribas A. Mechanisms of resistance to PD-1 and PD-L1 blockade. Cancer J. 2018;24(1):47-53.
  31. 31..
    Cui JW,Li Y,Yang Y,Yang HK,Dong JM,Xiao ZH, et al. Tumor immuno-therapy resistance: revealing the mechanism of PD-1/PD-L1-mediated tumor immune escape. Biomed Pharmacother. 2024;171:116203.
  32. 32..
    Dias DA,Urban S,Roessner U. A historical overview of natural products in drug discovery. Metabolites. 2012;2(2):303-36.
  33. 33..
    Niloy MS,Shakil MS,Alif MMH,Rosengren RJ. Using natural compounds to target KRAS mutated non-small cell lung cancer. Curr Med Chem.2021;28(39):8098-115.
  34. 34..
    Newman DJ,Cragg GM. Natural products as sources of new drugs over the nearly four decades from 01/1981 to 09/2019. J Nat Prod.2020;83(3):770-803.
  35. 35..
    Lee J,Han Y,Wang W,Jo H,Kim H,Kim S, et al. Phytochemicals in cancer immune checkpoint inhibitor therapy. Biomolecules. 2021;11(8):1107.
  36. 36..
    Chun KS,Kim DH,Raut PK,Surh YJ. Anticancer natural products target-ing immune checkpoint protein network. Semin Cancer Biol. 2022;86(Pt 3):1008-32.
  37. 37..
    Yang YSH,Li ZL,Shih YJ,Bennett JA,Whang-Peng J,Lin HY, et al. Herbal medicines attenuate PD-L1 expression to induce anti-proliferation in obesity-related cancers. Nutrients. 2019;11(12):2979.
  38. 38..
    Sasmal P,Kumar Babasahib S,Prashantha Kumar BR,Manjunathaiah RN. Biphenyl-based small molecule inhibitors: novel cancer immunothera-peutic agents targeting PD-1/PD-L1 interaction. Bioorg Med Chem.2022;73:117001.
  39. 39..
    Liu K,Sun Q,Liu Q,Li H,Zhang W,Sun C. Focus on immune checkpoint PD-1/PD-L1 pathway: new advances of polyphenol phytochemicals in tumor immunotherapy. Biomed Pharmacother. 2022;154:113618.
  40. 40..
    Ri MH,Ma J,Jin X. Development of natural products for anti-PD-1/PD-L1 immunotherapy against cancer. J Ethnopharmacol.2021;281:114370.
  41. 41..
    Patsoukis N,Wang Q,Strauss L,Boussiotis VA. Revisiting the PD-1 path-way. Sci Adv. 2020;6(38):eabd712.
  42. 42..
    Salmaninejad A,Valilou SF,Shabgah AG,Aslani S,Alimardani M,Pasdar A, et al. PD-1/PD-L1 pathway: basic biology and role in cancer immuno-therapy. J Cell Physiol. 2019;234(10):16824-37.
  43. 43..
    Liu J,Chen Z,Li Y,Zhao W,Wu J,Zhang Z. PD-1/PD-L1 checkpoint inhibitors in tumor immunotherapy. Front Pharmacol. 2021;12:731798.
  44. 44..
    Kuol N,Stojanovska L,Nurgali K,Apostolopoulos V. PD-1/PD-L1 in disease. Immunotherapy. 2018;10(2):149-60.
  45. 45..
    Li X,Shao C,Shi Y,Han W. Lessons learned from the blockade of immune checkpoints in cancer immunotherapy. J Hematol Oncol.2018;11(1):31.
  46. 46..
    Ghosh C,Luong G,Sun Y. A snapshot of the PD-1/PD-L1 pathway. J Cancer. 2021;12(9):2735-46.
  47. 47..
    Chen Y,Pei Y,Luo J,Huang Z,Yu J,Meng X. Looking for the optimal PD-1/PD-L1 inhibitor in cancer treatment: a comparison in basic struc-ture, function, and clinical practice. Front Immunol. 2020;11:1088.
  48. 48..
    O’Donnell JS,Long GV,Scolyer RA,Teng MWL,Smyth MJ. Resistance to PD1/PDL1 checkpoint inhibition. Cancer Treat Rev. 2017;52:71-81.
  49. 49..
    Kornepati AVR,Vadlamudi RK,Curiel TJ. Programmed death ligand 1 signals in cancer cells. Nat Rev Cancer. 2022;22(3):174-89.
  50. 50..
    Han Y,Liu D,Li L. PD-1/PD-L1 pathway: current researches in cancer. Am J Cancer Res. 2020;10(3):727-42.
  51. 51..
    Alspach E,Lussier DM,Schreiber RD. Interferon γ and its important roles in promoting and inhibiting spontaneous and therapeutic cancer immunity. Cold Spring Harb Perspect Biol. 2019;11(3):a028480.
  52. 52..
    Qian J,Wang C,Wang B,Yang J,Wang Y,Luo F, et al. The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy. J Neuroinflammation. 2018;15(1):290.
  53. 53..
    Kondo Y,Suzuki S,Ono S,Goto M,Miyabe S,Ogawa T, et al. In Situ PD-L1 expression in oral squamous cell carcinoma is induced by heter-ogeneous mechanisms among patients. Int J Mol Sci. 2022;23(8):4077.
  54. 54..
    Garcia-Diaz A,Shin DS,Moreno BH,Saco J,Escuin-Ordinas H,Rodriguez GA, et al. Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression. Cell Rep. 2017;19(6):1189-201.
  55. 55..
    Mühlbauer M,Fleck M,Schütz C,Weiss T,Froh M,Blank C, et al. PD-L1 is induced in hepatocytes by viral infection and by interferon-alpha and-gamma and mediates T cell apoptosis. J Hepatol. 2006;45(6):520-8.
  56. 56..
    Abiko K,Matsumura N,Hamanishi J,Horikawa N,Murakami R,Yamaguchi K, et al. IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer. Br J Cancer.2015;112(9):1501-9.
  57. 57..
    Uciechowski P,Dempke WCM. Interleukin-6: a masterplayer in the cytokine network. Oncology. 2020;98(3):131-7.
  58. 58..
    Li J,Xu J,Yan X,Jin K,Li W,Zhang R. Targeting interleukin-6 (IL-6) sensi-tizes anti-PD-L1 treatment in a colorectal cancer preclinical model. Med Sci Monit. 2018;24:5501-8.
  59. 59..
    Wertel I,Suszczyk D,Pawłowska A,Bilska M,Chudzik A,Skiba W, et al. Prognostic and clinical value of interleukin 6 and CD45+CD14+ inflam-matory cells with PD-L1+/PD-L2+ expression in patients with different manifestation of ovarian cancer. J Immunol Res. 2020;2020:1715064.
  60. 60..
    Chan LC,Li CW,Xia W,Hsu JM,Lee HH,Cha JH, et al. IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune eva-sion. J Clin Invest. 2019;129(8):3324-38.
  61. 61..
    Liu C,Yang L,Xu H,Zheng S,Wang Z,Wang S, et al. Systematic analysis of IL-6 as a predictive biomarker and desensitizer of immunotherapy responses in patients with non-small cell lung cancer. BMC Med.2022;20(1):187.
  62. 62..
    Zhang GQ,Jiao Q,Shen CT,Song HJ,Zhang HZ,Qiu ZL, et al. Interleukin 6 regulates the expression of programmed cell death ligand 1 in thy-roid cancer. Cancer Sci. 2021;112(3):997-1010.
  63. 63..
    Bloch O,Crane CA,Kaur R,Safaee M,Rutkowski MJ,Parsa AT. Glio-mas promote immunosuppression through induction of B7–H1 expression in tumor-associated macrophages. Clin Cancer Res.2013;19(12):3165-75.
  64. 64..
    Lamano JB,Lamano JB,Li YD,DiDomenico JD,Choy W,Veliceasa D, et al. Glioblastoma-derived IL-6 induces immunosuppressive peripheral myeloid cell PD-L1 and promotes tumor growth. Clin Cancer Res.2019;25(12):3643-57.
  65. 65..
    Liu S,Chen S,Yuan W,Wang H,Chen K,Li D, et al. PD-1/PD-L1 interac-tion up-regulates MDR1/P-gp expression in breast cancer cells via PI3K/Akt and MAPK/Erk pathways. Oncotarget. 2017;8(59):99901-12.
  66. 66..
    Sengal A,Velazquez J,Hahne M,Burke TM,Abhyankar H,Reyes R, et al. Overcoming T-cell exhaustion in LCH: PD-1 blockade and targeted MAPK inhibition are synergistic in a mouse model of LCH. Blood.2021;137(13):1777-91.
  67. 67..
    Stutvoet TS,Kol A,de Vries EG,de Bruyn M,Fehrmann RS,Terwiss-cha van Scheltinga AG, et al. MAPK pathway activity plays a key role in PD-L1 expression of lung adenocarcinoma cells. J Pathol.2019;249(1):52-64.
  68. 68..
    Loi S,Dushyanthen S,Beavis PA,Salgado R,Denkert C,Savas P, et al. RAS/MAPK activation is associated with reduced tumor-infiltrating lymphocytes in triple-negative breast cancer: therapeutic cooperation between MEK and PD-1/PD-L1 immune checkpoint inhibitors. Clin Cancer Res. 2016;22(6):1499-509.
  69. 69..
    Zhang Y,Velez-Delgado A,Mathew E,Li D,Mendez FM,Flannagan K, et al. Myeloid cells are required for PD-1/PD-L1 checkpoint activation and the establishment of an immunosuppressive environment in pancreatic cancer. Gut. 2017;66(1):124-36.
  70. 70..
    Tang YYY,He Y,Shi LL,Yang LLLL,Wang JJJJ,Lian Y, et al. Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression. Clin Cancer Res. 2021;8:1-15.
  71. 71..
    Tewari D,Patni P,Bishayee A,Sah AN,Bishayee A. Natural products targeting the PI3K-Akt-mTOR signaling pathway in cancer: a novel therapeutic strategy. Semin Cancer Biol. 2022;80:1-17.
  72. 72..
    Alzahrani AS. PI3K/Akt/mTOR inhibitors in cancer: at the bench and bedside. Semin Cancer Biol. 2019;59:125-32.
  73. 73..
    Aoki M,Fujishita T. Oncogenic roles of the PI3K/Akt/mTOR axis. Curr Top Microbiol Immunol. 2017;407:153-89.
  74. 74..
    Loibl S,Gianni L. HER2-positive breast cancer. Lancet.2017;389(10087):2415-29.
  75. 75..
    Yuan JQ,Ding NH,Xiao Z. The Hippo transducer YAP/TAZ as a bio-marker of therapeutic response and prognosis in trastuzumab-based neoadjuvant therapy treated HER2-positive breast cancer patients. Front Pharmacol. 2020;11:537265.
  76. 76..
    Patel PD,Yan P,Seidler PM,Patel HJ,Sun W,Yang C, et al. Paralog-selective Hsp90 inhibitors define tumor-specific regulation of HER2. Nat Chem Biol. 2013;9(11):677-84.
  77. 77..
    Zeng J,He SL,Li LJ,Wang C. Hsp90 up-regulates PD-L1 to promote HPV-positive cervical cancer via HER2/PI3K/Akt pathway. Mol Med.2021;27:130.
  78. 78..
    Wang F,Yang L,Xiao M,Zhang Z,Shen J,Anuchapreeda S, et al. PD-L1 regulates cell proliferation and apoptosis in acute myeloid leukemia by activating PI3K-Akt signaling pathway. Sci Rep. 2022;12(1):11444.
  79. 79..
    Fei Z,Deng Z,Zhou L,Li K,Xia X,Xie R. PD-L1 induces epithelial-mesen-chymal transition in nasopharyngeal carcinoma cells through activation of the PI3K/Akt pathway. Oncol Res. 2019;27(7):801-7.
  80. 80..
    Liu Y,Liu S,Wu C,Huang W,Xu B,Lian S, et al. PD-1-mediated PI3K/Akt/mTOR, caspase 9/caspase 3 and ERK pathways are involved in regulat-ing the apoptosis and proliferation of CD4+ and CD8+ T cells during BVDV infection in vitro. Front Immunol. 2020;11:467.
  81. 81..
    Wu J,Zhao X,Sun Q,Jiang Y,Zhang W,Luo J, et al. Synergic effect of PD-1 blockade and endostar on the PI3K/Akt/mTOR-mediated autophagy and angiogenesis in Lewis lung carcinoma mouse model. Biomed Pharmacother. 2020;125:109746.
  82. 82..
    Gao Y,Yang J,Cai Y,Fu S,Zhang N,Fu X, et al. IFN-γ-mediated inhibition of lung cancer correlates with PD-L1 expression and is regulated by PI3K-Akt signaling. Int J Cancer. 2018;143(4):931-43.
  83. 83..
    Hu X,Li J,Fu M,Zhao X,Wang W. The JAK/STAT signaling pathway: from bench to clinic. Signal Transduct Target Ther. 2021;6(1):402.
  84. 84..
    Owen KL,Brockwell NK,Parker BS. JAK-STAT signaling: a double-edged sword of immune regulation and cancer progression. Cancers (Basel).2019;11(12):2002.
  85. 85..
    Doi T,Ishikawa T,Okayama T,Oka K,Mizushima K,Yasuda T, et al. The JAK/STAT pathway is involved in the upregulation of PD-L1 expression in pancreatic cancer cell lines. Oncol Rep. 2017;37(3):1545-54.
  86. 86..
    Sasi B,Ethiraj P,Myers J,Lin A-P,Jiang S,Qiu Z, et al. Regulation of PD-L1 expression is a novel facet of cyclic-AMP-mediated immunosuppres-sion. Leukemia. 2021;35(7):1990-2001.
  87. 87..
    Zhu J,Li Y,Lv X. IL4I1 enhances PD-L1 expression through JAK/STAT signaling pathway in lung adenocarcinoma. Immunogenetics.2023;75(1):17-25.
  88. 88..
    Thiem A,Hesbacher S,Kneitz H,Di Primio T,Heppt MV,Hermanns HM, et al. IFN-gamma-induced PD-L1 expression in melanoma depends on p53 expression. J Exp Clin Cancer Res. 2019;38(1):397.
  89. 89..
    Bellucci R,Martin A,Bommarito D,Wang K,Hansen SH,Freeman GJ, et al. Interferon-γ-induced activation of JAK1 and JAK2 suppresses tumor cell susceptibility to NK cells through upregulation of PD-L1 expression. Oncoimmunology. 2015;4(6):e1008824.
  90. 90..
    Mimura K,Teh JL,Okayama H,Shiraishi K,Kua LF,Koh V, et al. PD-L1 expression is mainly regulated by interferon gamma associated with JAK-STAT pathway in gastric cancer. Cancer Sci. 2018;109(1):43-53.
  91. 91..
    Iwasaki T,Kohashi K,Toda Y,Ishihara S,Yamada Y,Oda Y. Association of PD-L1 and IDO1 expression with JAK-STAT pathway activation in soft-tissue leiomyosarcoma. J Cancer Res Clin Oncol. 2021;147(5):1451-63.
  92. 92..
    Sasidharan Nair V,Toor SM,Ali BR,Elkord E. Dual inhibition of STAT1 and STAT3 activation downregulates expression of PD-L1 in human breast cancer cells. Expert Opin Ther Targets. 2018;22(6):547-57.
  93. 93..
    Tao B,Shi J,Shuai S,Zhou H,Zhang H,Li B, et al. CYB561D2 up-regula-tion activates STAT3 to induce immunosuppression and aggression in gliomas. J Transl Med. 2021;19(1):338.
  94. 94..
    Mitchell S,Vargas J,Hoffmann A. Signaling via the NFκB system. Wiley Interdiscip Rev Syst Biol Med. 2016;8(3):227-41.
  95. 95..
    Zinatizadeh MR,Schock B,Chalbatani GM,Zarandi PK,Jalali SA,Miri SR. The nuclear factor kappa B (NF-κB) signaling in cancer development and immune diseases. Genes Dis. 2021;8(3):287-97.
  96. 96..
    Adhikari A,Xu M,Chen ZJ. Ubiquitin-mediated activation of TAK1 and IKK. Oncogene. 2007;26(22):3214-26.
  97. 97..
    Iwai K. Diverse ubiquitin signaling in NF-κB activation. Trends Cell Biol.2012;22(7):355-64.
  98. 98..
    Greten FR,Eckmann L,Greten TF,Park JM,Li ZW,Egan LJ, et al. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell. 2004;118(3):285-96.
  99. 99..
    Jardin F. NFκB pathway and Hodgkin lymphoma. Biomedicines.2022;10(9):2153.
  100. 100..
    Lam AR,Le BN,Ho SS,Shen YJ,Tang LF,Xiong GM, et al. RAE1 ligands for the NKG2D receptor are regulated by STING-dependent DNA sensor pathways in lymphoma. Cancer Res. 2014;74(8):2193-203.
  101. 101..
    Cai H,Yan L,Liu N,Xu M,Cai H. IFI16 promotes cervical cancer progres-sion by upregulating PD-L1 in immunomicroenvironment through STING-TBK1-NF-κB pathway. Biomed Pharmacother. 2020;123:109790.
  102. 102..
    Saliminejad K,Khorram Khorshid HR,Soleymani Fard S,Ghaffari SH. An overview of microRNAs: biology, functions, therapeutics, and analysis methods. J Cell Physiol. 2019;234(5):5451-65.
  103. 103..
    Iqbal MA,Arora S,Prakasam G,Calin GA,Syed MA. MicroRNA in lung cancer: role, mechanisms, pathways and therapeutic relevance. Mol Aspects Med. 2019;70:3-20.
  104. 104..
    Huang J,Weng Q,Shi Y,Mao W,Zhao Z,Wu R, et al. MicroRNA-155-5p suppresses PD-L1 expression in lung adenocarcinoma. FEBS Open Bio.2020;10(6):1065-71.
  105. 105..
    Zhang W,Xin J,Lai J,Zhang W. LncRNA LINC00184 promotes docetaxel resistance and immune escape via miR-105-5p/PD-L1 axis in prostate cancer. Immunobiology. 2022;227(1):152163.
  106. 106..
    Uhlén M,Fagerberg L,Hallström BM,Lindskog C,Oksvold P,Mardinoglu A, et al. Proteomics. Tissue-based map of the human proteome. Science. 2015;347(6220):1260419.
  107. 107..
    Cristescu R,Lee J,Nebozhyn M,Kim KM,Ting JC,Wong SS, et al. Molecu-lar analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat Med. 2015;21(5):449-56.
  108. 108..
    Miliotis C,Slack FJ. miR-105-5p regulates PD-L1 expression and tumor immunogenicity in gastric cancer. Cancer Lett. 2021;518:115-26.
  109. 109..
    Yao X,Tu Y,Xu Y,Guo Y,Yao F,Zhang X. Endoplasmic reticulum stress-induced exosomal miR-27a-3p promotes immune escape in breast cancer via regulating PD-L1 expression in macrophages. J Cell Mol Med.2020;24(17):9560-73.
  110. 110..
    Mestdagh P,Lefever S,Pattyn F,Ridzon D,Fredlund E,Fieuw A, et al. The microRNA body map: dissecting microRNA function through integra-tive genomics. Nucleic Acids Res. 2011;39(20):e136.
  111. 111..
    Boldrini L,Giordano M,Niccoli C,Melfi F,Lucchi M,Mussi A, et al. Role of microRNA-33a in regulating the expression of PD-1 in lung adenocarci-noma. Cancer Cell Int. 2017;17:105.
  112. 112..
    Costa C,Indovina P,Mattioli E,Forte IM,Iannuzzi CA,Luzzi L, et al. P53-regulated miR-320a targets PDL1 and is downregulated in malig-nant mesothelioma. Cell Death Dis. 2020;11(9):748.
  113. 113..
    Robinson EK,Covarrubias S,Carpenter S. The how and why of lncRNA function: an innate immune perspective. Biochim Biophys Acta Gene Regul Mech. 2020;1863(4):194419.
  114. 114..
    Tang Y,He Y,Shi L,Yang L,Wang J,Lian Y, et al. Co-expression of AFAP1-AS1 and PD-1 predicts poor prognosis in nasopharyngeal carcinoma. Oncotarget. 2017;8(24):39001-11.
  115. 115..
    Atianand MK,Fitzgerald KA. Long non-coding RNAs and con-trol of gene expression in the immune system. Trends Mol Med.2014;20(11):623-31.
  116. 116..
    Xiong F,Zhu K,Deng S,Huang H,Yang L,Gong Z, et al. AFAP1-AS1: a rising star among oncogenic long non-coding RNAs. Sci China Life Sci.2021;64(10):1602-11.
  117. 117..
    Zhang H,Xu HB,Kurban E,Luo HW. LncRNA SNHG14 promotes hepato-cellular carcinoma progression via H3K27 acetylation activated PABPC1 by PTEN signaling. Cell Death Dis. 2020;11(8):646.
  118. 118..
    Zhao L,Liu Y,Zhang J,Liu Y,Qi Q. LncRNA SNHG14/miR-5590-3p/ZEB1 positive feedback loop promoted diffuse large B cell lymphoma progression and immune evasion through regulating PD-1/PD-L1 checkpoint. Cell Death Dis. 2019;10(10):731.
  119. 119..
    Zhang C,Jiang F,Su C,Xie P,Xu L. Upregulation of long noncoding RNA SNHG20 promotes cell growth and metastasis in esophageal squamous cell carcinoma via modulating ATM-JAK-PD-L1 pathway. J Cell Biochem.2019;120(7):11642-50.
  120. 120..
    Maarouf M,Chen B,Chen Y,Wang X,Rai KR,Zhao Z, et al. Identifica-tion of lncRNA-155 encoded by MIR155HG as a novel regulator of innate immunity against influenza a virus infection. Cell Microbiol.2019;21(8):e13036.
  121. 121..
    Peng L,Chen Z,Chen Y,Wang X,Tang N. MIR155HG is a prognostic biomarker and associated with immune infiltration and immune checkpoint molecules expression in multiple cancers. Cancer Med.2019;8(17):7161-73.
  122. 122..
    Zhong Y,Yang L,Xiong F,He Y,Tang Y,Shi L, et al. Long non-coding RNA AFAP1-AS1 accelerates lung cancer cells migration and invasion by interacting with SNIP1 to upregulate c-Myc. Signal Transduct Target Ther. 2021;6(1):240.
  123. 123..
    Bo H,Gong Z,Zhang W,Li X,Zeng Y,Liao Q, et al. Upregulated long non-coding RNA AFAP1-AS1 expression is associated with progression and poor prognosis of nasopharyngeal carcinoma. Oncotarget.2015;6(24):20404-18.
  124. 124..
    Wang XS,Zhang Z,Wang HC,Cai JL,Xu QW,Li MQ, et al. Rapid iden-tification of UCA1 as a very sensitive and specific unique marker for human bladder carcinoma. Clin Cancer Res Off J Am Assoc Cancer Res.2006;12(16):4851-8.
  125. 125..
    Wang CJ,Zhu CC,Xu J,Wang M,Zhao WY,Liu Q, et al. The lncRNA UCA1 promotes proliferation, migration, immune escape and inhibits apop-tosis in gastric cancer by sponging anti-tumor miRNAs. Mol Cancer.2019;18(1):115.
  126. 126..
    Planes-Laine G,Rochigneux P,Bertucci F,Chrétien AS,Viens P,Sabatier R, et al. PD-1/PD-L1 targeting in breast cancer: the first clinical evidences are emerging: a literature review. Cancers (Basel). 2019;11(7):1033.
  127. 127..
    Page DB,Bear H,Prabhakaran S,Gatti-Mays ME,Thomas A,Cobain E, et al. Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer. NPJ Breast Cancer. 2019;5:34.
  128. 128..
    Ghebeh H,Mohammed S,Al-Omair A,Qattan A,Lehe C,Al-Qudaihi G, et al. The B7–H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia. 2006;8(3):190-8.
  129. 129..
    Wang Y,Li G. PD-1/PD-L1 blockade in cervical cancer: current studies and perspectives. Front Med. 2019;13(4):438-50.
  130. 130..
    Chen Z,Pang N,Du R,Zhu Y,Fan L,Cai D, et al. Elevated expression of programmed death-1 and programmed death ligand-1 negatively regulates immune response against cervical cancer cells. Mediators Inflamm. 2016;2016:6891482.
  131. 131..
    Koi M,Carethers JM. The colorectal cancer immune microenvironment and approach to immunotherapies. Future Oncol. 2017;13(18):1633-47.
  132. 132..
    Piawah S. Targeted therapy for colorectal cancer metastases: a review of current methods of molecularly targeted therapy and the use of tumor biomarkers in the treatment of metastatic colorectal cancer. Cancer.2019;125(23):4139-47.
  133. 133..
    Payandeh Z,Khalili S,Somi MH,Mard-Soltani M,Baghbanzadeh A,Hajiasgharzadeh K, et al. PD-1/PD-L1-dependent immune response in colorectal cancer. J Cell Physiol. 2020;235(7–8):5461-75.
  134. 134..
    Concha-Benavente F,Srivastava RM,Trivedi S,Lei Y,Chandran U,Seethala RR, et al. Identification of the cell-intrinsic and -extrinsic pathways downstream of EGFR and IFNγ that induce PD-L1 expression in head and neck Cancer. Cancer Res. 2016;76(5):1031-43.
  135. 135..
    Matsumoto K,Ema M,Agency T. Roles of VEGF-A signaling in develop-ment, regeneration, and tumors. J Biochem. 2014;156(1):1-10.
  136. 136..
    LeCouter J,Moritz DR,Li B,Phillips GL,Liang XH,Gerber HP, et al. Angiogenesis-independent endothelial protection of liver: role of VEGFR-1. Science. 2003;299(5608):890-3.
  137. 137..
    Ding BS,Nolan DJ,Butler JM,James D,Babazadeh AO,Rosenwaks Z, et al. Inductive angiocrine signals from sinusoidal endothelium are required for liver regeneration. Nature. 2010;468(7321):310-5.
  138. 138..
    Voron T,Colussi O,Marcheteau E,Pernot S,Nizard M,Pointet AL, et al. VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors. J Exp Med. 2015;212(2):139-48.
  139. 139..
    Zhang Y,Yuan Z,Jin Y,Zhang W,Yuan WE. Novel fluorinated spermine and small molecule PEI to deliver anti-PD-L1 and anti-VEGF siRNA for highly efficient tumor therapy. Pharmaceutics. 2021;13(12):2058.
  140. 140..
    Qiao XW,Jiang J,Pang X,Huang MC,Tang YJ,Liang XH, et al. The evolv-ing landscape of PD-1/PD-L1 pathway in head and neck cancer. Front Immunol. 2020;11:1721.
  141. 141..
    Denaro N,Merlano MC. Unexpected response with palliative conven-tional therapy in head and neck squamous cell carcinoma after anti-programmed death-1 progression. Head Neck. 2019;41(3):E42-7.
  142. 142..
    Parikh F,Duluc D,Imai N,Clark A,Misiukiewicz K,Bonomi M, et al. Chemoradiotherapy-induced upregulation of PD-1 antagonizes immunity to HPV-related oropharyngeal cancer. Cancer Res.2014;74(24):7205-16.
  143. 143..
    Fuereder T. Immunotherapy for head and neck squamous cell carci-noma. Memo. 2016;9:66-9.
  144. 144..
    Gavrielatou N,Doumas S,Economopoulou P,Foukas PG,Psyrri A. Bio-markers for immunotherapy response in head and neck cancer. Cancer Treat Rev. 2020;84:101977.
  145. 145..
    Zongyi Y,Xiaowu L. Immunotherapy for hepatocellular carcinoma. Cancer Lett. 2020;470:8-17.
  146. 146..
    Demirtas CO,Gunduz F. Programmed cell death 1 and hepatocellular carcinoma: an epochal story. J Gastrointest Cancer. 2021;52(4):1217-22.
  147. 147..
    Calderaro J,Rousseau B,Amaddeo G,Mercey M,Charpy C,Costentin C, et al. Programmed death ligand 1 expression in hepatocellular carci-noma: relationship with clinical and pathological features. Hepatology.2016;64(6):2038-46.
  148. 148..
    Yan Y,Zheng L,Du Q,Yan B,Geller DA. Interferon regulatory factor 1 (IRF-1) and IRF-2 regulate PD-L1 expression in hepato-cellular carcinoma (HCC) cells. Cancer Immunol Immunother.2020;69(9):1891-903.
  149. 149..
    Huang MY,Jiang XM,Wang BL,Sun Y,Lu JJ. Combination therapy with PD-1/PD-L1 blockade in non-small cell lung cancer: strategies and mechanisms. Pharmacol Ther. 2021;219:107694.
  150. 150..
    Yu H,Boyle TA,Zhou C,Rimm DL,Hirsch FR. PD-L1 expression in lung cancer. J Thorac Oncol. 2016;11(7):964-75.
  151. 151..
    Ji M,Liu Y,Li Q,Li XD,Zhao WQ,Zhang H, et al. PD-1/PD-L1 pathway in non-small-cell lung cancer and its relation with EGFR mutation. J Transl Med. 2015;13:5.
  152. 152..
    Dong Y,Wang Z,Mao F,Cai L,Dan H,Jiang L, et al. PD-1 blockade prevents the progression of oral carcinogenesis. Carcinogenesis.2021;42(6):891-902.
  153. 153..
    Liu S,Knochelmann HM,Lomeli SH,Hong A,Richardson M,Yang Z, et al. Response and recurrence correlates in individuals treated with neoadjuvant anti-PD-1 therapy for resectable oral cavity squamous cell carcinoma. Cell reports Med. 2021;2(10):100411.
  154. 154..
    Henriksen A,Dyhl-Polk A,Chen I,Nielsen D. Checkpoint inhibitors in pancreatic cancer. Cancer Treat Rev. 2019;78:17-30.
  155. 155..
    Geng L,Huang D,Liu J,Qian Y,Deng J,Li D, et al. B7–H1 up-regulated expression in human pancreatic carcinoma tissue associates with tumor progression. J Cancer Res Clin Oncol. 2008;134(9):1021-7.
  156. 156..
    Sharpe AH,Wherry EJ,Ahmed R,Freeman GJ. The function of pro-grammed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol. 2007;8(3):239-45.
  157. 157..
    Okazaki T,Honjo T. PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol. 2007;19(7):813-24.
  158. 158..
    Jiang LP,Yu XH,Chen JZ,Hu M,Zhang YK,Lin HL, et al. Histone dea-cetylase 3: a potential therapeutic target for atherosclerosis. Aging Dis. 2022;13(3):773-86.
  159. 159..
    Sarkar R,Banerjee S,Amin SA,Adhikari N,Jha T. Histone deacetylase 3 (HDAC3) inhibitors as anticancer agents: a review. Eur J Med Chem.2020;192:112171.
  160. 160..
    Hu G,He N,Cai C,Cai F,Fan P,Zheng Z, et al. HDAC3 modulates can-cer immunity via increasing PD-L1 expression in pancreatic cancer. Pancreatology. 2019;19(2):383-9.
  161. 161..
    Bieszczad KM,Bechay XK,Rusche JR,Jacques V,Kudugunti S,Miao W, et al. Histone deacetylase inhibition via RGFP966 releases the brakes on sensory cortical plasticity and the specificity of memory forma-tion. J Neurosci. 2015;35(38):13124-32.
  162. 162..
    Zhang X,Huang X,Xu J,Li E,Lao M,Tang T, et al. NEK2 inhibition triggers anti-pancreatic cancer immunity by targeting PD-L1. Nat Commun. 2021;12(1):4536.
  163. 163..
    Zhang Z,Cheng L,Li J,Qiao Q,Karki A,Allison DB, et al. Targeting PLK1 sensitizes pancreatic cancer to immune checkpoint therapy. Cancer Res. 2022;82(19):3532-48.
  164. 164..
    Aydin AM,Cheriyan S,Spiess PE. Treating advanced penile cancer:where do we stand in 2019? Curr Opin Support Palliat Care.2019;13(3):249-54.
  165. 165..
    Tang Y,Hu X,Wu K,Li X. Immune landscape and immunotherapy for penile cancer. Front Immunol. 2022;13:1055235.
  166. 166..
    Ahmed ME,Falasiri S,Hajiran A,Chahoud J,Spiess PE. The immune microenvironment in penile cancer and rationale for immunother-apy. J Clin Med. 2020;9(10):3334.
  167. 167..
    Deng C,Li Z,Guo S,Chen P,Chen X,Zhou Q, et al. Tumor PD-L1 expression is correlated with increased TILs and poor prog-nosis in penile squamous cell carcinoma. Oncoimmunology.2017;6(2):e1269047.
  168. 168..
    Junker K,Eckstein M,Fiorentino M,Montironi R. PD1/PD-L1 axis in uro-oncology. Curr Drug Targets. 2020;21(13):1293-300.
  169. 169..
    Davidsson S,Carlsson J,Giunchi F,Harlow A,Kirrander P,Rider J, et al. PD-L1 expression in men with penile cancer and its association with clinical outcomes. Eur Urol Oncol. 2019;2(2):214-21.
  170. 170..
    de Vries H-M,Ottenhof SR,Horenblas S,van der Heijden MS,Jordanova ES. Defining the tumor microenvironment of penile cancer by means of the cancer immunogram. Eur Urol Focus. 2019;5(5):718-21.
  171. 171..
    Lu Y,Wang Y,Su H,Li H. PD-L1 is associated with the prognosis of penile cancer: a systematic review and meta-analysis. Front Oncol.2022;12:1013806.
  172. 172..
    Aydin AM,Chahoud J,Adashek JJ,Azizi M,Magliocco A,Ross JS, et al. Understanding genomics and the immune environment of penile cancer to improve therapy. Nat Rev Urol. 2020;17(10):555-70.
  173. 173..
    Gu W,Zhu Y,Ye D. Beyond chemotherapy for advanced disease-the role of EGFR and PD-1 inhibitors. Transl Androl Urol. 2017;6(5):848-54.
  174. 174..
    Cao H,Wu T,Zhou X,Xie S,Sun H,Sun Y, et al. Progress of research on PD-1/PD-L1 in leukemia. Front Immunol. 2023;14:1265299.
  175. 175..
    Pianko MJ,Goldberg AD,Lesokhin AM. Clinical development of PD-1 blockade in hematologic malignancies. Cancer J. 2018;24(1):31-5.
  176. 176..
    Zheng C,You W,Wan P,Jiang X,Chen J,Zheng Y, et al. Clinicopatho-logical and prognostic significance of PD-L1 expression in sarcoma:a systematic review and meta-analysis. Medicine (Baltimore).2018;97(25):e11004.
  177. 177..
    Italiano A,Bellera C,D’Angelo S. PD-1/PD-L1 targeting in advanced soft-tissue sarcomas: a pooled analysis of phase II trials. J Hematol Oncol.2020;13(1):55.
  178. 178..
    Fazel M,Dufresne A,Vanacker H,Waissi W,Blay JY,Brahmi M. Immuno-therapy for soft tissue sarcomas: anti-PD1/PDL1 and Beyond. Cancers(Basel). 2023;15(6):1643.
  179. 179..
    Cunningham CR,Dodd L,Esebua M,Layfield LJ. PD-L1 expression in sarcomas: an immunohistochemical study and review of the literature. Ann Diagn Pathol. 2021;55:151823.
  180. 180..
    Hargadon KM,Johnson CE,Williams CJ. Immune checkpoint blockade therapy for cancer: an overview of FDA-approved immune checkpoint inhibitors. Int Immunopharmacol. 2018;62:29-39.
  181. 181..
    Reddy SM,Carroll E,Nanda R. Atezolizumab for the treatment of breast cancer. Expert Rev Anticancer Ther. 2020;20(3):151-8.
  182. 182..
    Roviello G,D’Angelo A,Generali D,Pittacolo M,Ganzinelli M,Iezzi G, et al. Avelumab in gastric cancer. Immunotherapy. 2019;11(9):759-68.
  183. 183..
    Naik pp. Cemiplimab in advanced cutaneous squamous cell carcinoma. Dermatol Ther. 2021;34(6):e15184.
  184. 184..
    Markham A. Dostarlimab: first approval. Drugs. 2021;81(10):1213-9.
  185. 185..
    Al-Salama ZT. Durvalumab: a review in extensive-stage SCLC. Target Oncol. 2021;16(6):857-64.
  186. 186..
    Smith KM,Desai J. Nivolumab for the treatment of colorectal cancer. Expert Rev Anticancer Ther. 2018;18(7):611-8.
  187. 187..
    Poole RM. Pembrolizumab: first global approval. Drugs.2014;74(16):1973-81.
  188. 188..
    Paz-Ares L,Dvorkin M,Chen Y,Reinmuth N,Hotta K,Trukhin D, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer(CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet.2019;394(10212):1929-39.
  189. 189..
    Powles T,Park SH,Voog E,Caserta C,Valderrama BP,Gurney H, et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med. 2020;383(13):1218-30.
  190. 190..
    Motzer RJ,Penkov K,Haanen J,Rini B,Albiges L,Campbell MT, et al. Ave-lumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380(12):1103-15.
  191. 191..
    Jackson-Spence F,Szabados B,Toms C,Yang YH,Sng C,Powles T. Ave-lumab in locally advanced or metastatic urothelial carcinoma. Expert Rev Anticancer Ther. 2022;22(2):135-40.
  192. 192..
    Migden MR,Rischin D,Schmults CD,Guminski A,Hauschild A,Lewis KD, et al. PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. N Engl J Med. 2018;379(4):341-51.
  193. 193..
    Valentin J,Gérard E,Ferte T,Prey S,Dousset L,Dutriaux C, et al. Real world safety outcomes using cemiplimab for cutaneous squamous cell carcinoma. J Geriatr Oncol. 2021;12(7):1110-3.
  194. 194..
    Costa B,Vale N. Dostarlimab: a review. Biomolecules. 2022;12(8):1031.
  195. 195..
    Kasherman L,Ahrari S,Lheureux S. Dostarlimab in the treatment of recurrent or primary advanced endometrial cancer. Future Oncol.2021;17(8):877-92.
  196. 196..
    Yadav R,Mathur I,Haokip HR,Pandey AK,Kumar V,Jain N. Dostarlimab:review on success story and clinical trials. Crit Rev Oncol Hematol.2024;198:104374.
  197. 197..
    Park UB,Jeong TJ,Gu N,Lee HT,Heo YS. Molecular basis of PD-1 block-ade by dostarlimab, the FDA-approved antibody for cancer immuno-therapy. Biochem Biophys Res Commun. 2022;599:31-7.
  198. 198..
    Mathieu L,Shah S,Pai-Scherf L,Larkins E,Vallejo J,Li X, et al. FDA approval summary: atezolizumab and durvalumab in combination with platinum-based chemotherapy in extensive stage small cell lung cancer. Oncologist. 2021;26(5):433-8.
  199. 199..
    Park S,Noh JM,Choi YL,Chi SA,Kim K,Jung HA, et al. Durvalumab with chemoradiotherapy for limited-stage small-cell lung cancer. Eur J Cancer. 2022;169:42-53.
  200. 200..
    Rizzo A,Ricci AD,Brandi G. Durvalumab: an investigational anti-PD-L1 antibody for the treatment of biliary tract cancer. Expert Opin Investig Drugs. 2021;30(4):343-50.
  201. 201..
    Chiew Woon L,Joycelyn Jie Xin L,Su Pin C. Nivolumab for the treatment of hepatocellular carcinoma. Expert Opin Biol Ther. 2020;20(7):687-93.
  202. 202..
    Finkelmeier F,Waidmann O,Trojan J. Nivolumab for the treat-ment of hepatocellular carcinoma. Expert Rev Anticancer Ther.2018;18(12):1169-75.
  203. 203..
    Reuss JE,Anagnostou V,Cottrell TR,Smith KN,Verde F,Zahurak M, et al. Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer. J Immunother cancer. 2020;8(2):e001282.
  204. 204..
    Paik J. Nivolumab plus relatlimab: first approval. Drugs.2022;82(8):925-31.
  205. 205..
    Patnaik A,Kang SP,Rasco D,Papadopoulos KP,Elassaiss-Schaap J,Beeram M, et al. Phase I study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in patients with advanced solid tumors. Clin cancer Res. 2015;21(19):4286-93.
  206. 206..
    Coupez D,Hulo P,Touchefeu Y,Bossard C,Bennouna J. Pembroli-zumab for the treatment of colorectal cancer. Expert Opin Biol Ther.2020;20(3):219-26.
  207. 207..
    Kwok G,Yau TCC,Chiu JW,Tse E,Kwong YL. Pembrolizumab (Keytruda). Hum Vaccines Immunother. 2016;12(11):2777-89.
  208. 208..
    de Sousa LG,Ferrarotto R. Pembrolizumab in the first-line treatment of advanced head and neck cancer. Expert Rev Anticancer Ther.2021;21(12):1321-31.
  209. 209..
    Burtness B,Harrington KJ,Greil R,Soulières D,Tahara M,de Castro GJ, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carci-noma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet (London, England). 2019;394(10212):1915-28.
  210. 210..
    Champiat S,Lambotte O,Barreau E,Belkhir R,Berdelou A,Carbonnel F, et al. Management of immune checkpoint blockade dysimmune toxici-ties: a collaborative position paper. Ann Oncol. 2016;27(4):559-74.
  211. 211..
    Grignani G,Rutkowski P,Lebbe C,Prinzi N,Grob J,Tanda ET, et al. 545 A phase 2 study of retifanlimab in patients with advanced or metastatic merkel cell carcinoma (MCC) (POD1UM-201). JITC. 2021;9(Suppl 3):A574-5.
  212. 212..
    Shen L,Kato K,Kim S-B,Ajani JA,Zhao K,He Z, et al. RATIONALE 302:randomized, phase 3 study of tislelizumab versus chemotherapy as second-line treatment for advanced unresectable/metastatic esopha-geal squamous cell carcinoma. J Clin Oncol. 2021;39(15):4012.
  213. 213..
    Keam SJ. Toripalimab: first global approval. Drugs. 2019;79(5):573-8.
  214. 214..
    Mai HQ,Chen QY,Chen D,Hu C,Yang K,Wen J, et al. Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial. Nat Med. 2021;27(9):1536-43.
  215. 215..
    Rajasekaran N,Wang X,Ravindranathan S,Chin DJ,Tseng SY,Klakamp SL, et al. Toripalimab, a therapeutic monoclonal anti-PD-1 antibody with high binding affinity to PD-1 and enhanced potency to activate human T cells. Cancer Immunol Immunother. 2024;73(3):60.
  216. 216..
    Kichenadasse G,Miners JO,Mangoni AA,Rowland A,Hopkins AM,Sorich MJ. Multiorgan immune-related adverse events dur-ing treatment with Atezolizumab. J Natl Compr Cancer Netw.2020;18(9):1191-9.
  217. 217..
    Costa M,Magalhães H. A curious case of diabetic ketoacidosis second-ary to avelumab. Cureus. 2024;16(6):e62240.
  218. 218..
    Liu G,Zhang S,Mo Z,Huang T,Yu Q,Lu X, et al. Association of thrombocytopenia with immune checkpoint inhibitors: a large-scale pharmacovigilance analysis based on the data from FDA adverse event reporting system database. Front Pharmacol. 2024;15:1407894.
  219. 219..
    Coombs MRP,Harrison ME,Hoskin DW. Apigenin inhibits the inducible expression of programmed death ligand 1 by human and mouse mam-mary carcinoma cells. Cancer Lett. 2016;380(2):424-33.
  220. 220..
    Liu Y,Liu X,Zhang N,Yin M,Dong J,Zeng Q, et al. Berberine diminishes cancer cell PD-L1 expression and facilitates antitumor immunity via inhibiting the deubiquitination activity of CSN5. Acta Pharm Sin B.2020;10(12):2299-312.
  221. 221..
    Kang DY,Sp N,Jo ES,Rugamba A,Hong DY,Lee HG, et al. The inhibi-tory mechanisms of tumor PD-L1 expression by natural bioactive gallic acid in non-small-cell lung cancer (NSCLC) cells. Cancers (Basel).2020;12(3):727.
  222. 222..
    Hu M,Yang J,Qu L,Deng X,Duan Z,Fu R, et al. Ginsenoside Rk1 induces apoptosis and downregulates the expression of PD-L1 by targeting the NF-κB pathway in lung adenocarcinoma. Food Funct.2020;11(1):456-71.
  223. 223..
    Kongtawelert P,Wudtiwai B,Shwe TH,Pothacharoen P,Phitak T. Inhibi-tory effect of hesperidin on the expression of programmed death ligand (PD-L1) in breast cancer. Molecules. 2020;25(2):252.
  224. 224..
    Hao H,Zhang Q,Zhu H,Wen Y,Qiu D,Xiong J, et al. Icaritin promotes tumor T-cell infiltration and induces antitumor immunity in mice. Eur J Immunol. 2019;49(12):2235-44.
  225. 225..
    Kim JH,Kim YS,Choi JG,Li W,Lee EJ,Park JW, et al. Kaempferol and its glycoside, kaempferol 7-o-rhamnoside, inhibit PD-1/PD-L1 interaction in vitro. Int J Mol Sci. 2020;21(9):3239.
  226. 226..
    Liu X,Xing Y,Li M,Zhang Z,Wang J,Ri M, et al. Licochalcone a inhibits proliferation and promotes apoptosis of colon cancer cell by targeting programmed cell death-ligand 1 via the NF-κB and Ras/Raf/MEK path-ways. J Ethnopharmacol. 2021;273:113989.
  227. 227..
    Jiang ZB,Wang WJ,Xu C,Xie YJ,Wang XR,Zhang YZ, et al. Luteolin and its derivative apigenin suppress the inducible PD-L1 expression to improve anti-tumor immunity in KRAS-mutant lung cancer. Cancer Lett.2021;515:36-48.
  228. 228..
    Peng M,Fan S,Li J,Zhou X,Liao Q,Tang F, et al. Programmed death-ligand 1 signaling and expression are reversible by lycopene via PI3K/Akt and Raf/MEK/Erk pathways in tongue squamous cell carcinoma. Genes Nutr. 2022;17(1):3.
  229. 229..
    Chen YC,He XL,Qi L,Shi W,Yuan LW,Huang MY, et al. Myricetin inhibits interferon-γ-induced PD-L1 and IDO1 expression in lung cancer cells. Biochem Pharmacol. 2022;197:114940.
  230. 230..
    Wang Z,Li MY,Zhang ZH,Zuo HX,Wang JY,Xing Y, et al. Panaxadiol inhibits programmed cell death-ligand 1 expression and tumour prolif-eration via hypoxia-inducible factor (HIF)-1α and STAT3 in human colon cancer cells. Pharmacol Res. 2020;155:104727.
  231. 231..
    Zhang YF,Zhang ZH,Li MY,Wang JY,Xing Y,Ri M, et al. Britannin stabi-lizes T cell activity and inhibits proliferation and angiogenesis by target-ing PD-L1 via abrogation of the crosstalk between Myc and HIF-1α in cancer. Phytomedicine. 2021;81:153425.
  232. 232..
    Jin Y,Zhan X,Zhang B,Chen Y,Liu C,Yu L. Polydatin exerts an antitumor effect through regulating the miR-382/PD-L1 axis in colorectal cancer. Cancer Biother Radiopharm. 2020;35(2):83-91.
  233. 233..
    Jing L,Lin J,Yang Y,Tao L,Li Y,Liu Z, et al. Quercetin inhibiting the PD-1/PD-L1 interaction for immune-enhancing cancer chemopreventive agent. Phytother Res. 2021;35(11):6441-51.
  234. 234..
    Lucas J,Hsieh TC,Halicka HD,Darzynkiewicz Z,Wu JM. Upregulation of PD-L1 expression by resveratrol and piceatannol in breast and colorec-tal cancer cells occurs via HDAC3/p300-mediated NF-κB signaling. Int J Oncol. 2018;53(4):1469-80.
  235. 235..
    Shi Y,Fu Y,Zhang X,Zhao G,Yao Y,Guo Y, et al. Romidepsin (FK228)regulates the expression of the immune checkpoint ligand PD-L1 and suppresses cellular immune functions in colon cancer. Cancer Immunol Immunother. 2021;70(1):61-73.
  236. 236..
    Peng F,Xiong L,Peng C. (-)-Sativan inhibits tumor development and regulates miR-200c/PD-L1 in triple negative breast cancer cells. Front Pharmacol. 2020;11:251.
  237. 237..
    Ruan Z,Liang M,Shang L,Lai M,Deng X,Su X. Shikonin-mediated PD-L1 degradation suppresses immune evasion in pancreatic cancer by inhibiting NF-κB/STAT3 and NF-κB/CSN5 signaling pathways. Pancrea-tology. 2021;21(3):630-41.
  238. 238..
    Rugamba A,Kang DY,Sp N,Jo ES,Lee JM,Bae SW, et al. Silibinin regu-lates tumor progression and tumorsphere formation by suppressing PD-L1 expression in non-small cell lung cancer (NSCLC) cells. Cells.2021;10(7):1632.
  239. 239..
    Sellam LS,Zappasodi R,Chettibi F,Djennaoui D,Yahi-Ait Mesbah N,Amir-Tidadini ZC, et al. Silibinin down-regulates PD-L1 expression in nasopharyngeal carcinoma by interfering with tumor cell glycolytic metabolism. Arch Biochem Biophys. 2020;690:108479.
  240. 240..
    Kuo CS,Yang CY,Lin CK,Lin GJ,Sytwu HK,Chen YW. Triptolide sup-presses oral cancer cell PD-L1 expression in the interferon-γ-modulated microenvironment in vitro, in vivo, and in clinical patients. Biomed Phar-macother. 2021;133:111057.
  241. 241..
    Liang Y,Li S,Zheng G,Zhang L. β-elemene suppresses the malignant behavior of esophageal cancer cells by regulating the phosphorylation of Akt. Acta Histochem. 2020;122(4):151538.
  242. 242..
    Williams EH,Williams CA,McLeod JD. Identification of PDL-1 as a novel biomarker of sensitizer exposure in dendritic-like cells. Toxicol In Vitro.2010;24(6):1727-35.
  243. 243..
    Hsu PY,Lin YH,Yeh EL,Lo HC,Hsu TH,Su CC. Cordycepin and a prepara-tion from Cordyceps militaris inhibit malignant transformation and proliferation by decreasing EGFR and IL-17RA signaling in a murine oral cancer model. Oncotarget. 2017;8(55):93712-28.
  244. 244..
    Zuo HX,Jin Y,Wang Z,Li MY,Zhang ZH,Wang JY, et al. Curcumol inhib-its the expression of programmed cell death-ligand 1 through crosstalk between hypoxia-inducible factor-1α and STAT3 (T705) signaling pathways in hepatic cancer. J Ethnopharmacol. 2020;257:112835.
  245. 245..
    Ravindran Menon D,Li Y,Yamauchi T,Osborne DG,Vaddi PK,Wempe MF, et al. EGCG inhibits tumor growth in melanoma by targeting JAK-STAT signaling and its downstream PD-L1/PD-L2-PD1 axis in tumors and enhancing cytotoxic T-cell responses. Pharmaceuticals (Basel).2021;14(11):1081.
  246. 246..
    Yang A,Li MY,Zhang ZH,Wang JY,Xing Y,Ri M, et al. Erianin regulates programmed cell death ligand 1 expression and enhances cytotoxic T lymphocyte activity. J Ethnopharmacol. 2021;273:113598.
  247. 247..
    Jiang ZB,Huang JM,Xie YJ,Zhang YZ,Chang C,Lai HL, et al. Evodi-amine suppresses non-small cell lung cancer by elevating CD8+ T cells and downregulating the MUC1-C/PD-L1 axis. J Exp Clin Cancer Res.2020;39(1):249.
  248. 248..
    Xing Y,Mi C,Wang Z,Zhang ZH,Li MY,Zuo HX, et al. Fraxinellone has anticancer activity in vivo by inhibiting programmed cell death-ligand 1 expression by reducing hypoxia-inducible factor-1α and STAT3. Phar-macol Res. 2018;135:166-80.
  249. 249..
    Hu X,Que W,Hirano H,Wang Z,Nozawa N,Ishii T, et al. 5-Ami-nolevulinic acid/sodium ferrous citrate enhanced the antitumor effects of programmed cell death-ligand 1 blockade by regulation of exhausted T cell metabolism in a melanoma model. Cancer Sci.2021;112(7):2652-63.
  250. 250..
    Hayakawa T,Yaguchi T,Kawakami Y. Enhanced anti-tumor effects of the PD-1 blockade combined with a highly absorptive form of curcumin targeting STAT3. Cancer Sci. 2020;111(12):4326-35.
  251. 251..
    Xue M,Liang H,Tang Q,Xue C,He X,Zhang L, et al. The protective and immunomodulatory effects of fucoidan against 7,12-Dimethyl benz[a]anthracene-Induced experimental mammary carcinogen-esis through the PD1/PDL1 signaling pathway in rats. Nutr Cancer.2017;69(8):1234-44.
  252. 252..
    Jiang X,Wu H,Zhao W,Ding X,You Q,Zhu F, et al. Lycopene improves the efficiency of anti-PD-1 therapy via activating IFN signaling of lung cancer cells. Cancer Cell Int. 2019;19:68.
  253. 253..
    Dutta R,Khalil R,Mayilsamy K,Green R,Howell M,Bharadwaj S, et al. Combination therapy of mithramycin a and immune checkpoint inhibitor for the treatment of colorectal cancer in an orthotopic murine model. Front Immunol. 2021;12:706133.
  254. 254..
    Guo Z,Wang H,Meng F,Li J,Zhang S. Combined trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer. J Transl Med. 2015;13:247.
  255. 255..
    Vita AA,Pullen NA. Exploring the mechanism of berberine-mediated Tfh cell immunosuppression. Phytomedicine. 2022;105:154343.
  256. 256..
    Wang Y,Liu Y,Du X,Ma H,Yao J. The anti-cancer mechanisms of berber-ine: a review. Cancer Manag Res. 2020;12:695-702.
  257. 257..
    Nishikawa H,Sakaguchi S. Regulatory T cells in cancer immunotherapy. Curr Opin Immunol. 2014;27:1-7.
  258. 258..
    Kumar V,Patel S,Tcyganov E,Gabrilovich DI. The nature of myeloid-derived suppressor cells in the tumor microenvironment. Trends Immunol. 2016;37(3):208-20.
  259. 259..
    Lim SO,Li CW,Xia W,Cha JH,Chan LC,Wu Y, et al. Deubiquitination and stabilization of PD-L1 by CSN5. Cancer Cell. 2016;30(6):925-39.
  260. 260..
    Chen Z,Vallega KA,Chen H,Zhou J,Ramalingam SS,Sun SY. The natural product berberine synergizes with osimertinib preferentially against MET-amplified osimertinib-resistant lung cancer via direct MET inhibition. Pharmacol Res. 2022;175:105998.
  261. 261..
    Yuan R,Tan Y,Sun PH,Qin B,Liang Z. Emerging trends and research foci of berberine on tumor from 2002 to 2021: a bibliometric article of the literature from WoSCC. Front Pharmacol. 2023;14:1122890.
  262. 262..
    Gavaraskar K,Dhulap S,Hirwani RR. Therapeutic and cosmetic applications of Evodiamine and its derivatives–a patent review. Fitoterapia. 2015;106:22-35.
  263. 263..
    Zhang L,Li L,Chen X,Yuan S,Xu T,Zhao W, et al. Evodiamine inhibits ESCC by inducing M-phase cell-cycle arrest via CUL4A/p53/p21 axis and activating noxa-dependent intrinsic and DR4-dependent extrin-sic apoptosis. Phytomedicine. 2023;108:154493.
  264. 264..
    Yu Y,Huang X,Liang C,Zhang P. Evodiamine impairs HIF1A histone lactylation to inhibit Sema3A-mediated angiogenesis and PD-L1 by inducing ferroptosis in prostate cancer. Eur J Pharmacol.2023;957:176007.
  265. 265..
    Jiang L,Li J,Gong W,Wang X,Zhou Y,Qiu J, et al. Evodiamine inhibits the expression of pd-l1 via the Pi3k/Akt signaling pathway to regu-late antitumor immunity in Melanoma. Available SSRN 4830808.
  266. 266..
    Imran M,Aslam Gondal T,Atif M,Shahbaz M,Batool Qaisarani T,Hanif Mughal M, et al. Apigenin as an anticancer agent. Phytother Res.2020;34(8):1812-28.
  267. 267..
    Salehi B,Venditti A,Sharifi-Rad M,Kręgiel D,Sharifi-Rad J,Durazzo A, et al. The therapeutic potential of apigenin. Int J Mol Sci.2019;20(6):1305.
  268. 268..
    Jiang ZQ,Li MH,Qin YM,Jiang HY,Zhang X,Wu MH. Luteolin inhibits tumorigenesis and induces apoptosis of non-small cell lung cancer cells via regulation of microRNA-34a-5p. Int J Mol Sci. 2018;19(2):447.
  269. 269..
    Jin W. Role of JAK/STAT3 signaling in the regulation of metastasis, the transition of cancer stem cells, and chemoresistance of cancer by epithelial-mesenchymal transition. Cells. 2020;9(1):217.
  270. 270..
    Luo F,Luo M,Rong QX,Zhang H,Chen Z,Wang F, et al. Niclosamide, an antihelmintic drug, enhances efficacy of PD-1/PD-L1 immune checkpoint blockade in non-small cell lung cancer. J Immunother cancer. 2019;7(1):245.
  271. 271..
    Xu L,Zhang Y,Tian K,Chen X,Zhang R,Mu X, et al. Apigenin sup-presses PD-L1 expression in melanoma and host dendritic cells to elicit synergistic therapeutic effects. J Exp Clin Cancer Res.2018;37(1):261.
  272. 272..
    Doyle AA,Stephens JC. A review of cinnamaldehyde and its derivatives as antibacterial agents. Fitoterapia. 2019;139:104405.
  273. 273..
    Chen BJ,Fu CS,Li GH,Wang XN,Lou HX,Ren DM, et al. Cinnamalde-hyde analogues as potential therapeutic agents. Mini Rev Med Chem.2017;17(1):33-43.
  274. 274..
    Shreaz S,Wani WA,Behbehani JM,Raja V,Irshad M,Karched M, et al. Cinnamaldehyde and its derivatives, a novel class of antifungal agents. Fitoterapia. 2016;112:116-31.
  275. 275..
    Zhu R,Liu H,Liu C,Wang L,Ma R,Chen B, et al. Cinnamaldehyde in diabetes: a review of pharmacology, pharmacokinetics and safety. Pharmacol Res. 2017;122:78-89.
  276. 276..
    Lin LT,Wu SJ,Lin CC. The anticancer properties and apoptosis-inducing mechanisms of cinnamaldehyde and the herbal prescription Huang-Lian-Jie-Du-Tang (Huáng Lián Jiě Dú Tang) in human hepatoma cells. J Tradit Complement Med. 2013;3(4):227-33.
  277. 277..
    Pervin M,Unno K,Takagaki A,Isemura M,Nakamura Y. Function of green tea catechins in the brain: epigallocatechin gallate and its metabolites. Int J Mol Sci. 2019;20(15):3630.
  278. 278..
    Khalatbary AR,Khademi E. The green tea polyphenolic catechin epigallocatechin gallate and neuroprotection. Nutr Neurosci.2020;23(4):281-94.
  279. 279..
    Aggarwal V,Tuli HS,Tania M,Srivastava S,Ritzer EE,Pandey A, et al. Molecular mechanisms of action of epigallocatechin gallate in cancer:recent trends and advancement. Semin Cancer Biol. 2020;80:256-75.
  280. 280..
    Farooqi AA,Pinheiro M,Granja A,Farabegoli F,Reis S,Attar R, et al. EGCG mediated targeting of deregulated signaling pathways and non-coding RNAs in different cancers: focus on JAK/STAT, Wnt/β-catenin, TGF/SMAD, NOTCH, SHH/GLI, and TRAIL mediated signaling pathways. Cancers (Basel). 2020;12(4):951.
  281. 281..
    Li D,Cao D,Sun Y,Cui Y,Zhang Y,Jiang J, et al. The roles of epigallocat-echin gallate in the tumor microenvironment, metabolic reprogram-ming, and immunotherapy. Front Immunol. 2024;15:1331641.
  282. 282..
    Kciuk M,Alam M,Ali N,Rashid S,Głowacka P,Sundaraj R, et al. Epigallocatechin-3-gallate therapeutic potential in cancer: mechanism of action and clinical implications. Molecules. 2023;28(13):5246.
  283. 283..
    Chen P,Wu Q,Feng J,Yan L,Sun Y,Liu S, et al. Erianin, a novel dibenzyl compound in dendrobium extract, inhibits lung cancer cell growth and migration via calcium/calmodulin-dependent ferroptosis. Signal Transduct Target Ther. 2020;5(1):51.
  284. 284..
    Kong JM,Goh NK,Chia LS,Chia TF. Recent advances in traditional plant drugs and orchids. Acta Pharmacol Sin. 2003;24(1):7-21.
  285. 285..
    Coelho MA,de Carné TS,Rana S,Zecchin D,Moore C,Molina-Arcas M, et al. Oncogenic RAS signaling promotes tumor immunoresistance by stabilizing PD-L1 mRNA. Immunity. 2017;47(6):1083-1099.e6.
  286. 286..
    Chen H,Pu S,Mei N,Liu X,He J,Zhang H, et al. Clinicopathologic analy-sis of PD-L1 and PD-L2 expression in renal cell carcinoma: association with oncogenic proteins status. Cancer Biomark. 2022;23:694-702.
  287. 287..
    Chen H,Pu S,Mei N,Liu X,He J,Zhang H. Identification of prognostic biomarkers among ICAMs in the breast cancer microenvironment. Cancer Biomark. 2022;35(4):379-93.
  288. 288..
    Jiang Y,Zhan H. Communication between EMT and PD-L1 signaling:new insights into tumor immune evasion. Cancer Lett. 2020;468:72-81.
  289. 289..
    Wang P,Jia X,Lu B,Huang H,Liu J,Liu X, et al. Erianin suppresses consti-tutive activation of MAPK signaling pathway by inhibition of CRAF and MEK1/2. Signal Transduct Target Ther. 2023;8(1):96.
  290. 290..
    Wianowska D,Olszowy-Tomczyk M. A concise profile of gallic acid-from its natural sources through biological properties and chemical methods of determination. Molecules. 2023;28(3):1186.
  291. 291..
    Badhani B,Sharma N,Kakkar R. Gallic acid: a versatile antioxidant with promising therapeutic and industrial applications. RSC Adv.2015;5:27540-57.
  292. 292..
    Kahkeshani N,Farzaei F,Fotouhi M,Alavi SS,Bahramsoltani R,Naseri R, et al. Pharmacological effects of gallic acid in health and diseases: a mechanistic review. Iran J Basic Med Sci. 2019;22(3):225-37.
  293. 293..
    Lasso P,Gomez-Cadena A,Urueña C,Donda A,Martinez-Usatorre A,Romero P, et al. An immunomodulatory gallotanin-rich fraction from caesalpinia spinosa enhances the therapeutic effect of anti-PD-L1 in melanoma. Front Immunol. 2020;11:584959.
  294. 294..
    Luo Z,Shi J,Jiang Q,Yu G,Li X,Yu Z, et al. Gallic acid enhances anti-lymphoma function of anti-CD19 CAR-T cells in vitro and in vivo. Mol Biomed. 2023;4(1):8.
  295. 295..
    Li C,Schluesener H. Health-promoting effects of the citrus flavanone hesperidin. Crit Rev Food Sci Nutr. 2017;57(3):613-31.
  296. 296..
    Wudtiwai B,Makeudom A,Krisanaprakornkit S,Pothacharoen P,Kongtawelert P. Anticancer activities of hesperidin via suppression of up-regulated programmed death-ligand 1 expression in oral cancer cells. Molecules. 2021;26(17):5345.
  297. 297..
    Xia R,Xu G,Huang Y,Sheng X,Xu X,Lu H. Hesperidin suppresses the migration and invasion of non-small cell lung cancer cells by inhibiting the SDF-1/CXCR-4 pathway. Life Sci. 2018;201:111-20.
  298. 298..
    Li J,Shen S,Liu Z,Zhao H,Liu S,Liu Q, et al. Synthesis and structure-activity analysis of icaritin derivatives as potential tumor growth inhibi-tors of hepatocellular carcinoma cells. J Nat Prod. 2023;86(2):290-306.
  299. 299..
    Yang XJ,Xi YM,Li ZJ. Icaritin: a novel natural candidate for hematologi-cal malignancies therapy. Biomed Res Int. 2019;2019:4860268.
  300. 300..
    Wang YX,Jin YY,Wang J,Zhao ZC,Xue KW,Xiong H, et al. Icaritin deriva-tive IC2 induces cytoprotective autophagy of breast cancer cells via SCD1 inhibition. Molecules. 2023;28(3):1-14.
  301. 301..
    Mo D,Zhu H,Wang J,Hao H,Guo Y,Wang J, et al. Icaritin inhibits PD-L1 expression by targeting protein IκB kinase α. Eur J Immunol.2021;51(4):978-88.
  302. 302..
    Dabeek WM,Marra MV. Dietary quercetin and kaempferol: bioavail-ability and potential cardiovascular-related bioactivity in humans. Nutrients. 2019;11(10):2288.
  303. 303..
    Imran M,Salehi B,Sharifi-Rad J,Aslam Gondal T,Saeed F,Imran A, et al. Kaempferol: a key emphasis to its anticancer potential. Molecules.2019;24(12):2277.
  304. 304..
    Alkandahri MY,Pamungkas BT,Oktoba Z,Shafirany MZ,Sulastri L,Arfania M, et al. Hepatoprotective effect of kaempferol: a review of the dietary sources, bioavailability, mechanisms of action, and safety. Adv Pharmacol Pharm Sci. 2023;2023:1387665.
  305. 305..
    Lu X,Wu X,Jing L,Tao L,Zhang Y,Huang R, et al. Network pharmacol-ogy analysis and experiments validation of the inhibitory effect of JianPi Fu Recipe on colorectal cancer LoVo cells metastasis and growth. Evid Based Complement Alternat Med. 2020;2020:4517483.
  306. 306..
    Bhatia HS,Apweiler M,Sun L,Baron J,Tirkey A,Fiebich BL. Licochalcone a inhibits prostaglandin E2 by targeting the MAPK pathway in LPS activated primary microglia. Molecules. 2023;28(4):1927.
  307. 307..
    Tuli HS,Garg VK,Mehta JK,Kaur G,Mohapatra RK,Dhama K, et al. Licorice (Glycyrrhiza glabra L.)-derived phytochemicals target multiple signaling pathways to confer oncopreventive and oncotherapeutic effects. Onco Targets Ther. 2022;15:1419-48.
  308. 308..
    Kim SH,Yang M,Xu JG,Yu X,Qian XJ. Role of licochalcone A on thymic stromal lymphopoietin expression: implications for asthma. Exp Biol Med (Maywood). 2015;240(1):26-33.
  309. 309..
    Zhang Y,Zhou SQ,Xie MM,Jiang QL,Yang N,Wu R, et al. Licochalcone a alleviates laser-induced choroidal neovascularization by inhibiting the endothelial-mesenchymal transition via PI3K/Akt signaling pathway. Exp Eye Res. 2023;226:109335.
  310. 310..
    Deng N,Qiao M,Li Y,Liang F,Li J,Liu Y. Anticancer effects of licochal-cones: a review of the mechanisms. Front Pharmacol. 2023;14:1074506.
  311. 311..
    Bürkle A,Brabeck C,Diefenbach J,Beneke S. The emerging role of poly(ADP-ribose) polymerase-1 in longevity. Int J Biochem Cell Biol.2005;37(5):1043-53.
  312. 312..
    Fu Y,Hsieh T,Guo J,Kunicki J,Lee MYWT,Darzynkiewicz Z, et al. Licochalcone-A, a novel flavonoid isolated from licorice root (Glycyrrhiza glabra), causes G2 and late-G1 arrests in androgen-independ-ent PC-3 prostate cancer cells. Biochem Biophys Res Commun.2004;322(1):263-70.
  313. 313..
    Çetinkaya M,Baran Y. Therapeutic potential of luteolin on cancer. Vac-cines. 2023;11(3):554.
  314. 314..
    Fu QT,Zhong XQ,Chen MY,Gu JY,Zhao J,Yu DH, et al. Luteolin-loaded nanoparticles for the treatment of melanoma. Int J Nanomed.2023;18:2053-68.
  315. 315..
    Hostetler GL,Ralston RA,Schwartz SJ. Flavones: food sources, bioavail-ability, metabolism, and bioactivity. Adv Nutr. 2017;8(3):423-35.
  316. 316..
    Imran M,Rauf A,Abu-Izneid T,Nadeem M,Shariati MA,Khan IA, et al. Luteolin, a flavonoid, as an anticancer agent: a review. Biomed Pharma-cother. 2019;112:108612.
  317. 317..
    Muruganathan N,Dhanapal AR,Baskar V,Muthuramalingam P,Selvaraj D,Aara H, et al. Recent updates on source, biosynthesis, and thera-peutic potential of natural flavonoid luteolin: a review. Metabolites.2022;12(11):1145.
  318. 318..
    Agraharam G,Girigoswami A,Girigoswami K. Myricetin: a multifunc-tional flavonol in biomedicine. Curr Pharmacol Rep. 2022;8(1):48-61.
  319. 319..
    Song X,Tan L,Wang M,Ren C,Guo C,Yang B, et al. Myricetin: a review of the most recent research. Biomed Pharmacother. 2021;134: 111017.
  320. 320..
    Gupta G,Siddiqui MA,Khan MM,Ajmal M,Ahsan R,Rahaman MA, et al. Current pharmacological trends on myricetin. Drug Res (Stuttg).2020;70(10):448-54.
  321. 321..
    Taheri Y,Suleria HAR,Martins N,Sytar O,Beyatli A,Yeskaliyeva B, et al. Myricetin bioactive effects: moving from preclinical evidence to poten-tial clinical applications. BMC Complement Med Ther. 2020;20(1):1-14.
  322. 322..
    Liu S,Wang C,Zhang Y,Zhang Y,Song Y,Jiang J, et al. Polydatin inhibits mitochondrial damage and mitochondrial ROS by promot-ing PINK1-Parkin-mediated mitophagy in allergic rhinitis. FASEB J.2023;37(4):e22852.
  323. 323..
    Du QH,Peng C,Zhang H. Polydatin: a review of pharmacology and pharmacokinetics. Pharm Biol. 2013;51(11):1347-54.
  324. 324..
    Chen XJ,He MJ,Zhou G. All-trans retinoic acid induces anti-tumor effects via STAT3 signaling inhibition in oral squamous cell carcinoma and oral dysplasia. J oral Pathol Med. 2019;48(9):832-9.
  325. 325..
    Yao H,Xia D,Li ZL,Ren L,Wang MM,Chen WS, et al. MiR-382 functions as tumor suppressor and chemosensitizer in colorectal cancer. Biosci Rep. 2019;39(8):BSR20180441.
  326. 326..
    Chen Y,Niu J,Li L,Li Z,Jiang J,Zhu M, et al. Polydatin executes antican-cer effects against glioblastoma multiforme by inhibiting the EGFR-Akt/ERK1/2/STAT3-SOX2/Snail signaling pathway. Life Sci. 2020;258:118158.
  327. 327..
    Li Y,Yao J,Han C,Yang J,Chaudhry MT,Wang S, et al. Quercetin, inflam-mation and immunity. Nutrients. 2016;8(3):167.
  328. 328..
    Sethi G,Rath P,Chauhan A,Ranjan A,Choudhary R,Ramniwas S, et al. Apoptotic mechanisms of quercetin in liver cancer: recent trends and advancements. Pharmaceutics. 2023;15(2):712.
  329. 329..
    Li Z,Gao WQ,Wang P,Wang TQ,Xu WC,Zhu XY, et al. Pentamethylquer-cetin inhibits hepatocellular carcinoma progression and adipocytes-induced PD-L1 expression via IFN-γ signaling. Curr Cancer Drug Targets.2020;20(11):868-74.
  330. 330..
    Khan F,Niaz K,Maqbool F,Ismail Hassan F,Abdollahi M,Nagulapalli Venkata KC, et al. Molecular targets underlying the anticancer effects of quercetin: an update. Nutrients. 2016;8(9):529.
  331. 331..
    Tang J,Diao P,Shu X,Li L,Xiong L. Quercetin and quercitrin attenu-ates the inflammatory response and oxidative stress in LPS-induced RAW2647 cells: in vitro assessment and a theoretical model. Biomed Res Int. 2019;2019:7039802.
  332. 332..
    Chen T,Zhang X,Zhu G,Liu H,Chen J,Wang Y, et al. Quercetin inhibits TNF-α induced HUVECs apoptosis and inflammation via downregulat-ing NF-kB and AP-1 signaling pathway in vitro. Medicine (Baltimore).2020;99(38):e22241.
  333. 333..
    Qiu D,Yan X,Xiao X,Zhang G,Wang Y,Cao J, et al. To explore immune synergistic function of quercetin in inhibiting breast cancer cells. Can-cer Cell Int. 2021;21(1):632.
  334. 334..
    Breuss JM,Atanasov AG,Uhrin P. Resveratrol and its effects on the vascular system. Int J Mol Sci. 2019;20(7):1523.
  335. 335..
    Venkat R,Verma E,Daimary UD,Kumar A,Girisa S,Dutta U, et al. The journey of resveratrol from vineyards to clinics. Cancer Invest.2023;41(2):183-220.
  336. 336..
    Chimento A,D’Amico M,De Luca A,Conforti FL,Pezzi V,De Amicis F. Resveratrol, epigallocatechin gallate and curcumin for cancer therapy:challenges from their pro-apoptotic properties. Life. 2023;13(2):1-24.
  337. 337..
    Ko JH,Sethi G,Um JY,Shanmugam MK,Arfuso F,Kumar AP, et al. The role of resveratrol in cancer therapy. Int J Mol Sci. 2017;18(12):2589.
  338. 338..
    Bishayee A. Cancer prevention and treatment with resveratrol: from rodent studies to clinical trials. Cancer Prev Res (Phila). 2009;2(5):409-18.
  339. 339..
    Lin CC,Chin YT,Shih YJ,Chen YR,Chung YY,Lin CY, et al. Resveratrol antagonizes thyroid hormone-induced expression of checkpoint and proliferative genes in oral cancer cells. J Dent Sci. 2019;14(3):255-62.
  340. 340..
    Verdura S,Cuyàs E,Cortada E,Brunet J,Lopez-Bonet E,Martin-Castillo B, et al. Resveratrol targets PD-L1 glycosylation and dimeri-zation to enhance antitumor T-cell immunity. Aging (Albany NY).2020;12(1):8-34.
  341. 341..
    Banik K,Ranaware AM,Harsha C,Nitesh T,Girisa S,Deshpande V, et al. Piceatannol: a natural stilbene for the prevention and treatment of cancer. Pharmacol Res. 2020;153:104635.
  342. 342..
    Han X,Zhao N,Zhu W,Wang J,Liu B,Teng Y. Resveratrol attenuates TNBC lung metastasis by down-regulating PD-1 expression on pulmo-nary T cells and converting macrophages to M1 phenotype in a murine tumor model. Cell Immunol. 2021;368:104423.
  343. 343..
    Pradhan R,Paul S,Acharya SS,Sinha S,Dash SR,Kundu CN. Nano for-mulated resveratrol inhibits PD-L1 in oral cancer cells by deregulating the association between tumor associated macrophages and cancer associated fibroblasts through IL-6/JAK2/STAT3 signaling axis. J Nutr Biochem. 2024;125:109568.
  344. 344..
    Hasan N,Osman H,Mohamad S,Chong WK,Awang K,Zahariluddin ASM. The chemical components of Sesbania grandiflora root and their antituberculosis activity. Pharmaceuticals. 2012;5(8):882-9.
  345. 345..
    Ha H,Shim KS,An H,Kim T,Ma JY. Water extract of Spatholobus suberectus inhibits osteoclast differentiation and bone resorption. BMC Complement Altern Med. 2013;13:112.
  346. 346..
    Huang Y,Chen L,Feng L,Guo F,Li Y. Characterization of total phenolic constituents from the stems of Spatholobus suberectus using LC-DAD-MSn and their inhibitory effect on human neutrophil elastase activity. Molecules. 2013;18(7):7549-56.
  347. 347..
    Beavon IR. The E-cadherin-catenin complex in tumour metastasis:structure, function and regulation. Eur J Cancer. 2000;36:1607-20.
  348. 348..
    Ramis-Conde I,Chaplain MAJ,Anderson ARA,Drasdo D. Multi-scale modelling of cancer cell intravasation: the role of cadherins in metasta-sis. Phys Biol. 2009;6(1):16008.
  349. 349..
    Mastron JK,Siveen KS,Sethi G,Bishayee A. Silymarin and hepatocellular carcinoma: a systematic, comprehensive, and critical review. Anticancer Drugs. 2015;26(5):475-86.
  350. 350..
    Si L,Fu J,Liu W,Hayashi T,Nie Y,Mizuno K, et al. Silibinin inhibits migra-tion and invasion of breast cancer MDA-MB-231 cells through induc-tion of mitochondrial fusion. Mol Cell Biochem. 2020;463(1–2):189-201.
  351. 351..
    Guo C,He J,Song X,Tan L,Wang M,Jiang P, et al. Pharmacological prop-erties and derivatives of shikonin-a review in recent years. Pharmacol Res. 2019;149:104463.
  352. 352..
    Boulos JC,Rahama M,Hegazy MEF,Efferth T. Shikonin derivatives for cancer prevention and therapy. Cancer Lett. 2019;459:248-67.
  353. 353..
    Lin H,Ma X,Yang X,Chen Q,Wen Z,Yang M, et al. Natural shikonin and acetyl-shikonin improve intestinal microbial and protein composition to alleviate colitis-associated colorectal cancer. Int Immunopharmacol.2022;111:109097.
  354. 354..
    Wang Z,Cui Q,Shi L,Zhang M,Song P,Duan D, et al. Network pharma-cology-based prediction and verification of shikonin for treating colo-rectal cancer. Recent Pat Anticancer Drug Discov. 2022;17(3):297-311.
  355. 355..
    Olatunde OZ,Yong J,Lu C,Ming Y. A review on shikonin and its deriva-tives as potent anticancer agents targeted against topoisomerases. Curr Med Chem. 2023;31(8):920-37.
  356. 356..
    Bai Z,Yao C,Zhu J,Xie Y,Ye XY,Bai R, et al. Anti-tumor drug discovery based on natural product β-elemene: anti-tumor mechanisms and structural modification. Molecules. 2021;26(6):1499.
  357. 357..
    Han B,Wang T,Xue Z,Wen T,Lu L,Meng J, et al. Elemene nanoemulsion inhibits metastasis of breast cancer by ROS scavenging. Int J Nanomed.2021;16:6035-48.
  358. 358..
    Jiang Z,Jacob JA,Loganathachetti DS,Nainangu P,Chen B. β-Elemene:mechanistic studies on cancer cell interaction and its chemosensitiza-tion effect. Front Pharmacol. 2017;8:105.
  359. 359..
    Mohammadlou H,Hamzeloo-Moghadam M,Yami A,Feizi F,Moeinifard M,Gharehbaghian A. Britannin a sesquiterpene lactone from inula aucheriana exerted an anti-leukemic effect in acute lymphoblastic leu-kemia (ALL) cells and enhanced the sensitivity of the cells to vincristine. Nutr Cancer. 2022;74(3):965-77.
  360. 360..
    Moeinifard M,Hassan ZM,Fallahian F,Hamzeloo-Moghadam M,Taghikhani M. Britannin induces apoptosis through Akt-FOXO1 pathway in human pancreatic cancer cells. Biomed Pharmacother.2017;94:1101-10.
  361. 361..
    Bailly C. Anticancer targets and signaling pathways activated by britan-nin and related pseudoguaianolide sesquiterpene lactones. Biomedi-cines. 2021;9(10):1325.
  362. 362..
    Mohammadlou H,Hamzeloo-Moghadam M,Mohammadi MH,Yami A,Gharehbaghian A. Britannin, a sesquiterpene lactone induces ROS-dependent apoptosis in NALM-6, REH, and JURKAT cell lines and produces a synergistic effect with vincristine. Mol Biol Rep.2021;48(9):6249-58.
  363. 363..
    Yu YH,Zhang HJ,Yang F,Xu L,Liu H. Curcumol, a major terpenoid from Curcumae Rhizoma, attenuates human uterine leiomyoma cell development via the p38MAPK/NF-κB pathway. J Ethnopharmacol.2023;310:116311.
  364. 364..
    Zhang Y,Peng F,Yu C. Therapeutic potential of Curcuma oil and its terpenoids in gynecological cancers. Biomed Pharmacother.2023;157:114016.
  365. 365..
    Zhao P,Qiu J,Pan C,Tang Y,Chen M,Song H, et al. Potential roles and molecular mechanisms of bioactive ingredients in Curcumae Rhizoma against breast cancer. Phytomedicine. 2023;114:154810.
  366. 366..
    Asgharzadeh MR,Pourseif MM,Barar J,Eskandani M,Jafari Niya M,Mashayekhi MR, et al. Functional expression and impact of testis-spe-cific gene antigen 10 in breast cancer: a combined in vitro and in silico analysis. Bioimpacts. 2019;9(3):145-59.
  367. 367..
    Yoon JS,Sung SH,Kim YC. Neuroprotective limonoids of root bark of Dictamnus dasycarpus. J Nat Prod. 2008;71(2):208-11.
  368. 368..
    Wang S,Bao J,Li J,Li W,Tian M,Qiu C, et al. Fraxinellone induces hepa-totoxicity in zebrafish through oxidative stress and the transporters pathway. Molecules. 2022;27(9):2647.
  369. 369..
    Chen Y,Ruan J,Sun F,Wang H,Yang S,Zhang Y, et al. Anti-inflammatory limonoids from cortex dictamni. Front Chem. 2020;8:73.
  370. 370..
    Shi J,Sun S,Xing S,Huang C,Huang Y,Wang Q, et al. Fraxinellone inhibits progression of glioblastoma via regulating the SIRT3 signaling pathway. Biomed Pharmacother. 2022;153:113416.
  371. 371..
    Bailly C,Vergoten G. Fraxinellone: from pesticidal control to cancer treatment. Pestic Biochem Physiol. 2020;168:104624.
  372. 372..
    Zhou H,Liu Q,Zhang J,Yao J,Wang C,Zhang Y, et al. Cytochrome P450-mediated bioactivation: implication for the liver injury induced by fraxinellone, a bioactive constituent from dictamni cortex. Chem Res Toxicol. 2020;33(7):1960-8.
  373. 373..
    Khalaf RA,Awad M. Lycopene as a potential bioactive compound:chemistry, extraction, and anticancer prospective. Curr Cancer Drug Targets. 2023;23(8):634-42.
  374. 374..
    Wang R,Lu X,Yu R. Lycopene inhibits epithelial-mesenchymal transi-tion and promotes apoptosis in oral cancer via PI3K/Akt/m-TOR signal pathway. Drug Des Devel Ther. 2020;14:2461-71.
  375. 375..
    Ozkan G,Günal-Köroğlu D,Karadag A,Capanoglu E,Cardoso SM,Al-Omari B, et al. A mechanistic updated overview on lycopene as potential anticancer agent. Biomed Pharmacother. 2023;161:114428.
  376. 376..
    Gao J,Zhang Y,Liu X,Wu X,Huang L,Gao W. Triptolide: pharmaco-logical spectrum, biosynthesis, chemical synthesis and derivatives. Theranostics. 2021;11(15):7199-221.
  377. 377..
    Wei YM,Wang YH,Xue HQ,Luan ZH,Liu BW,Ren JH. Triptolide, a poten-tial autophagy modulator. Chin J Integr Med. 2019;25(3):233-40.
  378. 378..
    Hou W,Liu B,Xu H. Triptolide: medicinal chemistry, chemical biology and clinical progress. Eur J Med Chem. 2019;176:378-92.
  379. 379..
    Zhang L,Yu JS. Triptolide reverses helper T cell inhibition and down-regulates IFN-γ induced PD-L1 expression in glioma cell lines. J Neu-rooncol. 2019;143(3):429-36.
  380. 380..
    Elshafay A,Tinh NX,Salman S,Shaheen YS,Othman EB,Elhady MT, et al. Ginsenoside Rk1 bioactivity: a systematic review. PeerJ. 2017;5:e3993.
  381. 381..
    Choi K. Botanical characteristics, pharmacological effects and medicinal components of Korean Panax ginseng C A Meyer. Acta Pharmacol Sin.2008;29(9):1109-18.
  382. 382..
    An X,Fu R,Ma P,Ma X,Fan D. Ginsenoside Rk1 inhibits cell proliferation and promotes apoptosis in lung squamous cell carcinoma by calcium signaling pathway. RSC Adv. 2019;9(43):25107-18.
  383. 383..
    Ryoo N,Rahman MA,Hwang H,Ko SK,Nah SY,Kim HC, et al. Ginse-noside Rk1 is a novel inhibitor of NMDA receptors in cultured rat hip-pocampal neurons. J Ginseng Res. 2020;44(3):490-5.
  384. 384..
    Ernst E. Panax ginseng: an overview of the clinical evidence. J Ginseng Res. 2010;34:259-63.
  385. 385..
    Xu L,Xiao S,Lee JJ,Jiang H,Li X,Zhang X, et al. In vivo metabolites of panaxadiol inhibit hepg-2 cell proliferation by inducing G1 arrest and ROS-mediated apoptosis. J Agric Food Chem. 2022;70(37):11560-71.
  386. 386..
    Kang N,Gao H,He L,Liu Y,Fan H,Xu Q, et al. Ginsenoside Rb1 is an immune-stimulatory agent with antiviral activity against enterovirus 71. J Ethnopharmacol. 2021;266:113401.
  387. 387..
    Lv Y,Zhang Y,Feng J,Zhao T,Zhao J,Ge Y, et al. (20R)-panaxadiol as a natural active component with anti-obesity effects on ob/ob mice via modulating the gut microbiota. Molecules. 2022;27(8):2502.
  388. 388..
    Kwak JY. Fucoidan as a marine anticancer agent in preclinical develop-ment. Mar Drugs. 2014;12(2):851-70.
  389. 389..
    Zayed A,El-Aasr M,Ibrahim ARS,Ulber R. Fucoidan characterization:determination of purity and physicochemical and chemical properties. Mar Drugs. 2020;18(11):571.
  390. 390..
    El Rashed Z,Lupidi G,Kanaan H,Grasselli E,Canesi L,Khalifeh H, et al. Antioxidant and antisteatotic activities of a new fucoidan extracted from ferula hermonis roots harvested on lebanese mountains. Mol-ecules. 2021;26(4):1161.
  391. 391..
    Fitton HJ,Stringer DS,Park AY,Karpiniec SN. Therapies from Fucoidan:new developments. Mar Drugs. 2019;17(10):571.
  392. 392..
    Fitton JH,Acqua GD,Gardiner V,Karpiniec SS,Stringer DN,Davis E. Topical benefits of two fucoidan-rich extracts from marine macroalgae. Cosmetics. 2015;2:66-81.
  393. 393..
    Chauvierre C,Aid-Launais R,Aerts J,Chaubet F,Maire M,Chollet L, et al. Pharmaceutical development and safety evaluation of a GMP-grade fucoidan for molecular diagnosis of cardiovascular diseases. Mar Drugs.2019;17(12):699.
  394. 394..
    van Weelden G,Bobi M,Okła K,van Weelden WJ,Romano A,Pijnenborg JMA. Fucoidan structure and activity in relation to anti-cancer mecha-nisms. Mar Drugs. 2019;17(1):32.
  395. 395..
    Etman SM,Elnaggar YSR,Abdallah OY. Fucoidan, a natural biopolymer in cancer combating: from edible algae to nanocarrier tailoring. Int J Biol Macromol. 2020;147:799-808.
  396. 396..
    Teruya K,Kusumoto Y,Eto H,Nakamichi N,Shirahata S. Selective sup-pression of cell growth and programmed cell death-ligand 1 expression in HT1080 fibrosarcoma cells by low molecular weight fucoidan extract. Mar Drugs. 2019;17(7):421.
  397. 397..
    Donald S,Verschoyle RD,Greaves P,Colombo T,Zucchetti M,Falcioni C, et al. Dietary agent indole-3-carbinol protects female rats against the hepatotoxicity of the antitumor drug ET-743 (trabectidin) with-out compromising efficacy in a rat mammary carcinoma. Int J Cancer.2004;111(6):961-7.
  398. 398..
    Taamma A,Misset JL,Riofrio M,Guzman C,Brain E,Lopez Lazaro L, et al. Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-h continuous infusion in patients with solid tumors. J Clin Oncol. 2001;19(5):1256-65.
  399. 399..
    Delaloge S,Yovine A,Taamma A,Riofrio M,Brain E,Raymond E, et al. Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients–preliminary evidence of activity. J Clin Oncol. 2001;19(5):1248-55.
  400. 400..
    Jimeno JM. A clinical armamentarium of marine-derived anti-cancer compounds. Anticancer Drugs. 2002;13(Suppl 1):S15-9.
  401. 401..
    Banerjee P,Zhang R,Ivan C,Galletti G,Clise-Dwyer K,Barbaglio F, et al. Trabectedin reveals a strategy of immunomodulation in chronic lymphocytic leukemia. Cancer Immunol Res. 2019;7(12):2036-51.
  402. 402..
    D’Incalci M,Badri N,Galmarini CM,Allavena P. Trabectedin, a drug acting on both cancer cells and the tumour microenvironment. Br J Cancer. 2014;111(4):646-50.
  403. 403..
    Ashraf SA,Elkhalifa AEO,Siddiqui AJ,Patel M,Awadelkareem AM,Snoussi M, et al. Cordycepin for health and wellbeing: a potent bioactive metabolite of an entomopathogenic medicinal fungus cordyceps with its nutraceutical and therapeutic potential. Mol-ecules. 2020;25(12):2735.
  404. 404..
    Cunningham KG,Manson W,Spring FS,Hutchinson SA. Cordycepin, a metabolic product isolated from cultures of Cordyceps militaris (Linn.)link. Nature. 1950;166(4231):949.
  405. 405..
    Pan BS,Wang YK,Lai MS,Mu YF,Huang BM. Cordycepin induced MA-10 mouse Leydig tumor cell apoptosis by regulating p38 MAPKs and PI3K/Akt signaling pathways. Sci Rep. 2015;5:13372.
  406. 406..
    Cheng YH,Hsieh YC,Yu YH. Effect of cordyceps militaris hot water extract on immunomodulation-associated gene expression in broil-ers, gallus gallus. J Poult Sci. 2019;56(2):128-39.
  407. 407..
    Radhi M,Ashraf S,Lawrence S,Tranholm AA,Wellham PAD,Hafeez A, et al. A systematic review of the biological effects of cordycepin. Molecules. 2021;26(19):5886.
  408. 408..
    Xia C,Chen P,Mei S,Ning L,Lei C,Wang J, et al. Photo-crosslinked HAMA hydrogel with cordycepin encapsulated chitosan micro-spheres for osteoarthritis treatment. Oncotarget. 2017;8(2):2835-49.
  409. 409..
    Dong Y,Jing T,Meng Q,Liu C,Hu S,Ma Y, et al. Studies on the antidiabetic activities of Cordyceps militaris extract in diet-strep-tozotocin-induced diabetic Sprague-Dawley rats. Biomed Res Int.2014;2014:160980.
  410. 410..
    Khan MA,Tania M. Cordycepin and kinase inhibition in cancer. Drug Discov Today. 2023;28(3):103481.
  411. 411..
    Zavala K,Lee J,Chong J,Sharma M,Eilers H,Schumacher MA. The anticancer antibiotic mithramycin-A inhibits TRPV1 expression in dorsal root ganglion neurons. Neurosci Lett. 2014;578:211-6.
  412. 412..
    Rao KV,Cullen WP,Sobin BA. A new antibiotic with antitumor proper-ties. Antibiot Chemother (Northfield, Ill). 1962;12:182-6.
  413. 413..
    Demicheli C,Garnier-Suillerot A. Mithramycin: a very strong metal chelating agent. Biochim Biophys Acta. 1993;1158(1):59-64.
  414. 414..
    Sachrajda I,Ratajewski M. Mithramycin a suppresses expression of the human melanoma-associated gene ABCB8. Mol Genet Genomics.2011;285(1):57-65.
  415. 415..
    Gong J,Ji Y,Liu X,Zheng Y,Zhen Y. Mithramycin suppresses tumor growth by regulating CD47 and PD-L1 expression. Biochem Pharma-col. 2022;197:114894.
  416. 416..
    Choi ES,Nam JS,Jung JY,Cho NP,Cho SD. Modulation of specificity protein 1 by mithramycin A as a novel therapeutic strategy for cervi-cal cancer. Sci Rep. 2014;4:7162.
  417. 417..
    Frye R,Myers M,Axelrod KC,Ness EA,Piekarz RL,Bates SE, et al. Romidepsin: a new drug for the treatment of cutaneous T-cell lym-phoma. Clin J Oncol Nurs. 2012;16(2):195-204.
  418. 418..
    Ueda H,Nakajima H,Hori Y,Fujita T,Nishimura M,Goto T, et al. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum no. 968. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity. J Antibiot (Tokyo). 1994;47(3):301-10.
  419. 419..
    Smolewski P,Robak T. The discovery and development of romidep-sin for the treatment of T-cell lymphoma. Expert Opin Drug Discov.2017;12(8):859-73.
  420. 420..
    Ueda H,Manda T,Matsumoto S,Mukumoto S,Nishigaki F,Kawamura I, et al. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum no. 968. III. Antitumor activities on experimental tumors in mice. J Antibiot (Tokyo). 1994;47(3):315-23.
  421. 421..
    Petrich A,Nabhan C. Use of class I histone deacetylase inhibi-tor romidepsin in combination regimens. Leuk Lymphoma.2016;57(8):1755-65.
  422. 422..
    Li X,Su X,Liu R,Pan Y,Fang J,Cao L, et al. HDAC inhibition potentiates anti-tumor activity of macrophages and enhances anti-PD-L1-mediated tumor suppression. Oncogene. 2021;40(10):1836-50.
  423. 423..
    Woods DM,Sodré AL,Villagra A,Sarnaik A,Sotomayor EM,Weber J. HDAC inhibition upregulates PD-1 ligands in melanoma and aug-ments immunotherapy with PD-1 blockade. Cancer Immunol Res.2015;3(12):1375-85.
  424. 424..
    Patsoukis N,Brown J,Petkova V,Liu F,Li L,Boussiotis VA. Selective effects of PD-1 on Akt and Ras pathways regulate molecular components of the cell cycle and inhibit T cell proliferation. Sci Signal. 2012;5(230):ra46.
  425. 425..
    Patsoukis N,Bardhan K,Chatterjee P,Sari D,Liu B,Bell LN, et al. PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation. Nat Commun. 2015;6:6692.
  426. 426..
    Hashimoto M,Kamphorst AO,Im SJ,Kissick HT,Pillai RN,Ramalingam SS, et al. CD8 T Cell exhaustion in chronic infection and cancer: oppor-tunities for interventions. Annu Rev Med. 2018;69:301-18.
  427. 427..
    West EE,Jin HT,Rasheed AU,Penaloza-Macmaster P,Ha SJ,Tan WG, et al. PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells. J Clin Invest. 2013;123(6):2604-15.
  428. 428..
    Howley R,Chandratre S,Chen B. 5-aminolevulinic acid as a theranostic agent for tumor fluorescence imaging and photodynamic therapy. Bioengineering. 2023;10(4):496.
  429. 429..
    Wang P,Wang B,Zhang L,Liu X,Shi L,Kang X, et al. Clinical practice Guidelines for 5-Aminolevulinic acid photodynamic therapy for acne vulgaris in China. Photodiagnosis Photodyn Ther. 2023;41:103261.
  430. 430..
    Chen YX,Gao QY,Zou TH,Wang BM,Liu SD,Sheng JQ, et al. Berberine versus placebo for the prevention of recurrence of colorectal adenoma:a multicentre, double-blinded, randomised controlled study. Lancet Gastroenterol Hepatol. 2020;5(3):267-75.
  431. 431..
    Qian Y,Kang Z,Zhao L,Chen H,Zhou C,Gao Q, et al. Berberine might block colorectal carcinogenesis by inhibiting the regula-tion of B-cell function by Veillonella parvula. Chin Med J (Engl).2023;136(22):2722-31.
  432. 432..
    Espiritu MJ,Chen J,Yadav J,Larkin M,Pelletier RD,Chan JM, et al. Mechanisms of herb-drug interactions involving cinnamon and CYP2A6: focus on time-dependent inhibition by cinnamaldehyde and 2-methoxycinnamaldehyde. Drug Metab Dispos. 2020;48(10):1028-43.
  433. 433..
    Howells LM,Berry DP,Elliott PJ,Jacobson EW,Hoffmann E,Hegarty B, et al. Phase I randomized, double-blind pilot study of micronized resveratrol (SRT501) in patients with hepatic metastases–safety, pharmacokinetics, and pharmacodynamics. Cancer Prev Res (Phila).2011;4(9):1419-25.
  434. 434..
    Popat R,Plesner T,Davies F,Cook G,Cook M,Elliott P, et al. A phase 2 study of SRT501 (resveratrol) with bortezomib for patients with relapsed and or refractory multiple myeloma. Br J Haematol. 2013;160(5):714-7.
  435. 435..
    Flaig TW,Glodé M,Gustafson D,van Bokhoven A,Tao Y,Wilson S, et al. A study of high-dose oral silybin-phytosome followed by prostatectomy in patients with localized prostate cancer. Prostate. 2010;70(8):848-55.
  436. 436..
    Zhuang E,Uchio E,Lilly M,Zi X,Fruehauf JP. A phase II study of doc-etaxel plus lycopene in metastatic castrate resistant prostate cancer. Biomed Pharmacother. 2021;143:112226.
  437. 437..
    Tsai HL,Tai CJ,Huang CW,Chang FR,Wang JY. Efficacy of low-molecu-lar-weight fucoidan as a supplemental therapy in metastatic colorectal cancer patients: a double-blind randomized controlled trial. Mar Drugs.2017;15(4):122.
  438. 438..
    Demetri GD,Chawla SP,von Mehren M,Ritch P,Baker LH,Blay JY, et al. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthra-cyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol. 2009;27(25):4188-96.
  439. 439..
    Tewari D,Rawat P,Singh PK. Adverse drug reactions of anticancer drugs derived from natural sources. Food Chem Toxicol. 2019;123:522-35.
  440. 440..
    Wen L,Tong F,Zhang R,Chen L,Huang Y,Dong X. The research progress of PD-1/PD-L1 inhibitors enhancing radiotherapy efficacy. Front Oncol.2021;11:799957.
  441. 441..
    Mole RH. Whole body irradiation; radiobiology or medicine?. Br J Radiol.1953;26(305):234-41.
  442. 442..
    Gong J,Le TQ,Massarelli E,Hendifar AE,Tuli R. Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving antican-cer combination. J Immunother Cancer. 2018;6(1):46.

続きを読む

The above content is generated by Large Model Translation. The translated content is for reference only. We do not assume any commercial or legal responsibilty for any consequences arising from the use of our website